{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:19:17Z","timestamp":1793744357017,"version":"4.6.1"},"reference-count":499,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001409","name":"Department of Science and Technology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","award":["CRG\/2020\/005433"],"award-info":[{"award-number":["CRG\/2020\/005433"]}],"id":[{"id":"10.13039\/501100001409","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["5\/13\/46\/2022\/NCD-III"],"award-info":[{"award-number":["5\/13\/46\/2022\/NCD-III"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"DOI":"10.1186\/s12943-025-02400-z","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T01:02:56Z","timestamp":1759885376000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["Overcoming resistance to anti-PD-L1 immunotherapy: mechanisms, combination strategies, and future directions"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5319-1918","authenticated-orcid":false,"given":"Kartik","family":"Mandal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7625-5830","authenticated-orcid":false,"given":"Ganesh Kumar","family":"Barik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8899-4518","authenticated-orcid":false,"given":"Manas Kumar","family":"Santra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,8]]},"reference":[{"key":"2400_CR1","doi-asserted-by":"crossref","unstructured":"Hanahan D, Weinberg RA. Hallmarks of Cancer: The Next Generation. Cell. 2011;144:646\u201374. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0092867411001279.","DOI":"10.1016\/j.cell.2011.02.013"},{"key":"2400_CR2","doi-asserted-by":"crossref","unstructured":"Wu Z, Xia F, Lin R. Global burden of cancer and associated risk factors in 204 countries and territories, 1980\u20132021: a systematic analysis for the GBD 2021. J Hematol Oncol . 2024;17:119. Available from: https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-024-01640-8.","DOI":"10.1186\/s13045-024-01640-8"},{"key":"2400_CR3","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"2400_CR4","doi-asserted-by":"crossref","unstructured":"Janku F. Tumor heterogeneity in the clinic: is it a real problem? Ther Adv Med Oncol . 2014;6:43\u201351. Available from: http:\/\/journals.sagepub.com\/doi\/10.1177\/1758834013517414.","DOI":"10.1177\/1758834013517414"},{"key":"2400_CR5","unstructured":"National Cancer Institute. Types of cancer treatment. Cancer.gove. 2020;1\u20134. Available from: https:\/\/www.cancer.gov\/about-cancer\/treatment\/types."},{"key":"2400_CR6","doi-asserted-by":"crossref","unstructured":"Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39:1\u201310. Available from: http:\/\/www.cell.com\/article\/S1074761313002963\/fulltext.","DOI":"10.1016\/j.immuni.2013.07.012"},{"key":"2400_CR7","doi-asserted-by":"crossref","unstructured":"Galassi C, Chan TA, Vitale I, Galluzzi L. The hallmarks of cancer immune evasion. Cancer Cell . 2024;42:1825\u201363. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1535610824003581.","DOI":"10.1016\/j.ccell.2024.09.010"},{"key":"2400_CR8","doi-asserted-by":"crossref","unstructured":"Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol . 2020;17:807\u201321. Available from: https:\/\/www.nature.com\/articles\/s41423-020-0488-6.","DOI":"10.1038\/s41423-020-0488-6"},{"key":"2400_CR9","doi-asserted-by":"crossref","unstructured":"Hunter P. The fourth pillar: Despite some setbacks in the clinic, immunotherapy has made notable progress toward becoming an additional therapeutic option against cancer. EMBO Rep . 2017;18:1889\u201392. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29021204.","DOI":"10.15252\/embr.201745172"},{"key":"2400_CR10","doi-asserted-by":"crossref","unstructured":"Kalia V, Penny LA, Yuzefpolskiy Y, Baumann FM, Sarkar S. Quiescence of Memory CD8+ T Cells Is Mediated by Regulatory T Cells through Inhibitory Receptor CTLA-4. Immunity . 2015;42:1116\u201329. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1074761315002216.","DOI":"10.1016\/j.immuni.2015.05.023"},{"key":"2400_CR11","doi-asserted-by":"crossref","unstructured":"Fallarino F, Grohmann U, Hwang KW, Orabona C, Vacca C, Bianchi R, et al. Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol . 2003;4:1206\u201312. Available from: https:\/\/www.nature.com\/articles\/ni1003.","DOI":"10.1038\/ni1003"},{"key":"2400_CR12","doi-asserted-by":"crossref","unstructured":"Munn DH, Shafizadeh E, Attwood JT, Bondarev I, Pashine A, Mellor AL. Inhibition of T Cell Proliferation by Macrophage Tryptophan Catabolism. J Exp Med . 1999;189:1363\u201372. Available from: https:\/\/rupress.org\/jem\/article\/189\/9\/1363\/25860\/Inhibition-of-T-Cell-Proliferation-by-Macrophage.","DOI":"10.1084\/jem.189.9.1363"},{"key":"2400_CR13","doi-asserted-by":"crossref","unstructured":"Kennedy PT, Saulters EL, Duckworth AD, Lim YJ, Woolley JF, Slupsky JR, et al. Soluble CTLA-4 attenuates T cell activation and modulates anti-tumor immunity. Mol Ther . 2024;32:457\u201368. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001623006615.","DOI":"10.1016\/j.ymthe.2023.11.028"},{"key":"2400_CR14","doi-asserted-by":"crossref","unstructured":"Schneider H, Downey J, Smith A, Zinselmeyer BH, Rush C, Brewer JM, et al. Reversal of the TCR Stop Signal by CTLA-4. Science (80- ) . 2006;313:1972\u20135. Available from: https:\/\/www.science.org\/doi\/10.1126\/science.1131078.","DOI":"10.1126\/science.1131078"},{"key":"2400_CR15","doi-asserted-by":"crossref","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711\u201323. Available from: https:\/\/www.nejm.org\/doi\/full\/10.1056\/nejmoa1003466.","DOI":"10.1056\/NEJMoa1003466"},{"key":"2400_CR16","doi-asserted-by":"crossref","unstructured":"Page DB, Postow MA, Callahan MK, Allison JP, Wolchok JD. Immune modulation in cancer with antibodies. Annu Rev Med. 2014;65:185\u2013202. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/24188664\/.","DOI":"10.1146\/annurev-med-092012-112807"},{"key":"2400_CR17","doi-asserted-by":"crossref","unstructured":"Ljunggren HG, Jonsson R, H\u00f6glund P. Seminal immunologic discoveries with direct clinical implications: The 2018 Nobel Prize in Physiology or Medicine honours discoveries in cancer immunotherapy. Scand J Immunol. 2018;88:e12731. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1111\/sji.12731.","DOI":"10.1111\/sji.12731"},{"key":"2400_CR18","doi-asserted-by":"crossref","unstructured":"Wolchok JD, Hodi FS, Weber JS, Allison JP, Urba WJ, Robert C, et al. Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci . 2013;1291:1\u201313. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23772560.","DOI":"10.1111\/nyas.12180"},{"key":"2400_CR19","doi-asserted-by":"crossref","unstructured":"Tang J, Shalabi A, Hubbard-Lucey VM. Comprehensive analysis of the clinical immuno-oncology landscape. Ann Oncol . 2018;29:84\u201391. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419350203.","DOI":"10.1093\/annonc\/mdx755"},{"issue":"11","key":"2400_CR20","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.3390\/biomedicines9111687","volume":"9","author":"B Henriques","year":"2021","unstructured":"Henriques B, Mendes F, Martins D. Immunotherapy in breast cancer: when, how, and what challenges? Biomedicines. 2021;9(11):1687.","journal-title":"Biomedicines"},{"key":"2400_CR21","doi-asserted-by":"crossref","unstructured":"Ai L, Xu A, Xu J. Roles of PD-1\/PD-L1 Pathway: Signaling, Cancer, and Beyond. 2020. p. 33\u201359. Available from: http:\/\/link.springer.com\/10.1007\/978-981-15-3266-5_3.","DOI":"10.1007\/978-981-15-3266-5_3"},{"key":"2400_CR22","doi-asserted-by":"crossref","unstructured":"Sadeghi Rad H, Monkman J, Warkiani ME, Ladwa R, O\u2019Byrne K, Rezaei N, et al. Understanding the tumor microenvironment for effective immunotherapy. Med Res Rev. 2021;41:1474. Available from: https:\/\/www.pmc\/articles\/PMC8247330\/.","DOI":"10.1002\/med.21765"},{"key":"2400_CR23","doi-asserted-by":"crossref","unstructured":"Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat Med . 2002;8:793\u2013800. Available from: https:\/\/www.nature.com\/articles\/nm730.","DOI":"10.1038\/nm730"},{"key":"2400_CR24","doi-asserted-by":"crossref","unstructured":"Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, et al. Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation. J Exp Med . 2000;192:1027\u201334. Available from: https:\/\/rupress.org\/jem\/article\/192\/7\/1027\/8251\/Engagement-of-the-Pd-1-Immunoinhibitory-Receptor.","DOI":"10.1084\/jem.192.7.1027"},{"key":"2400_CR25","doi-asserted-by":"crossref","unstructured":"Shiravand Y, Khodadadi F, Kashani SMA, Hosseini-Fard SR, Hosseini S, Sadeghirad H, et al. Immune Checkpoint Inhibitors in Cancer Therapy. Curr Oncol. 2022;29:3044\u201360. Available from: https:\/\/www.mdpi.com\/1718-7729\/29\/5\/247\/htm.","DOI":"10.3390\/curroncol29050247"},{"key":"2400_CR26","doi-asserted-by":"crossref","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, Hui R, Cs\u0151szi T, F\u00fcl\u00f6p A, et al. Pembrolizumab versus Chemotherapy for PD-L1\u2013Positive Non\u2013Small-Cell Lung Cancer. N Engl J Med . 2016;375:1823\u201333. Available from: http:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa1606774.","DOI":"10.1056\/NEJMoa1606774"},{"key":"2400_CR27","doi-asserted-by":"crossref","unstructured":"Fusi A, Festino L, Botti G, Masucci G, Melero I, Lorigan P, et al. PD-L1 expression as a potential predictive biomarker . Lancet Oncol. 2015. p. 1285\u20137. Available from: https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2016.67.2477.","DOI":"10.1016\/S1470-2045(15)00307-1"},{"key":"2400_CR28","doi-asserted-by":"crossref","unstructured":"Doroshow DB, Bhalla S, Beasley MB, Sholl LM, Kerr KM, Gnjatic S, et al. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat Rev Clin Oncol . 2021;18:345\u201362. Available from: https:\/\/www.nature.com\/articles\/s41571-021-00473-5.","DOI":"10.1038\/s41571-021-00473-5"},{"key":"2400_CR29","doi-asserted-by":"crossref","unstructured":"Yang X, Jiang L, Zhang X, Peng J, Qian H, Huang L, et al. Soluble PD-L1 as a novel biomarker predicts poor outcomes and disease progression in de novo myelodysplastic syndromes. Biomark Res . 2024;12:115. Available from: https:\/\/biomarkerres.biomedcentral.com\/articles\/10.1186\/s40364-024-00665-y.","DOI":"10.1186\/s40364-024-00665-y"},{"key":"2400_CR30","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","volume":"14","author":"SP Patel","year":"2015","unstructured":"Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther. 2015;14:847\u201356.","journal-title":"Mol Cancer Ther"},{"key":"2400_CR31","doi-asserted-by":"crossref","unstructured":"Fusi A, Festino L, Botti G, Masucci G, Melero I, Lorigan P, et al. PD-L1 expression as a potential predictive biomarker. Lancet Oncol. 2015;16:1285\u20137. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/26433815\/.","DOI":"10.1016\/S1470-2045(15)00307-1"},{"key":"2400_CR32","doi-asserted-by":"crossref","unstructured":"Davis AA, Patel VG. The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors. J Immunother Cancer. 2019;7. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/31655605\/.","DOI":"10.1186\/s40425-019-0768-9"},{"key":"2400_CR33","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1038\/s41388-020-01611-6","volume":"40","author":"JE Grossman","year":"2021","unstructured":"Grossman JE, Vasudevan D, Joyce CE, Hildago M. Is PD-L1 a consistent biomarker for anti-PD-1 therapy? The model of balstilimab in a virally-driven tumor. Oncogene. 2021;40:1393\u20135. https:\/\/doi.org\/10.1038\/s41388-020-01611-6.","journal-title":"Oncogene"},{"key":"2400_CR34","doi-asserted-by":"publisher","first-page":"19738","DOI":"10.18632\/oncotarget.7582","volume":"7","author":"F Passiglia","year":"2016","unstructured":"Passiglia F, Bronte G, Bazan V, Natoli C, Rizzo S, Galvano A, et al. PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis. Oncotarget. 2016;7:19738\u201347.","journal-title":"Oncotarget"},{"key":"2400_CR35","doi-asserted-by":"crossref","unstructured":"Cottrell TR, Lotze MT, Ali A, Bifulco CB, Capitini CM, Chow LQM, et al. Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols. J Immunother Cancer . 2025;13:e010928. Available from: https:\/\/www.jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2024-010928.","DOI":"10.1136\/jitc-2024-010928"},{"key":"2400_CR36","doi-asserted-by":"crossref","unstructured":"Mansfield AS, Murphy SJ, Peikert T, Yi ES, Vasmatzis G, Wigle DA, et al. Heterogeneity of Programmed Cell Death Ligand 1 Expression in Multifocal Lung Cancer. Clin Cancer Res . 2016;22:2177\u201382. Available from: https:\/\/aacrjournals.org\/clincancerres\/article\/22\/9\/2177\/79707\/Heterogeneity-of-Programmed-Cell-Death-Ligand-1.","DOI":"10.1158\/1078-0432.CCR-15-2246"},{"key":"2400_CR37","doi-asserted-by":"crossref","unstructured":"Szekely B, Bossuyt V, Li X, Wali VB, Patwardhan GA, Frederick C, et al. Immunological differences between primary and metastatic breast cancer. Ann Oncol . 2018;29:2232\u20139. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419318782.","DOI":"10.1093\/annonc\/mdy399"},{"key":"2400_CR38","doi-asserted-by":"crossref","unstructured":"Moutafi MK, Tao W, Huang R, Haberberger J, Alexander B, Ramkissoon S, et al. Comparison of programmed death-ligand 1 protein expression between primary and metastatic lesions in patients with lung cancer. J Immunother Cancer. 2021;9. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/33833050\/.","DOI":"10.1136\/jitc-2020-002230"},{"key":"2400_CR39","doi-asserted-by":"crossref","unstructured":"Torlakovic E, Lim HJ, Adam J, Barnes P, Bigras G, Chan AWH, et al. \u201cInterchangeability\u201d of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy. Mod Pathol. 2019;33:4\u201317. Available from: https:\/\/www.nature.com\/articles\/s41379-019-0327-4.","DOI":"10.1038\/s41379-019-0327-4"},{"key":"2400_CR40","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1038\/s41379-020-0644-7","volume":"34","author":"EJ de Ruiter","year":"2021","unstructured":"de Ruiter EJ, Mulder FJ, Koomen BM, Speel EJ, van den Hout MFCM, de Roest RH, et al. Comparison of three PD-L1 immunohistochemical assays in head and neck squamous cell carcinoma (HNSCC). Mod Pathol. 2021;34:1125\u201332.","journal-title":"Mod Pathol"},{"key":"2400_CR41","doi-asserted-by":"crossref","unstructured":"He Y, Zhang X, Zhu M, He W, Hua H, Ye F, et al. Soluble PD-L1: a potential dynamic predictive biomarker for immunotherapy in patients with proficient mismatch repair colorectal cancer. J Transl Med . 2023 [cited 2023 Feb 27];21:1\u201313. Available from: https:\/\/link.springer.com\/articles\/10.1186\/s12967-023-03879-0.","DOI":"10.1186\/s12967-023-03879-0"},{"key":"2400_CR42","doi-asserted-by":"crossref","unstructured":"Scott ML, Scorer P, Lawson N, Ratcliffe MJ, Barker C, Rebelatto M, et al. Assessment of heterogeneity of PD-L1 expression in NSCLC, HNSCC, and UC with Ventana SP263 assay. J Clin Oncol . 2017;35:e14502\u2013e14502. Available from: http:\/\/ascopubs.org\/doi\/10.1200\/JCO.2017.35.15_suppl.e14502.","DOI":"10.1200\/JCO.2017.35.15_suppl.e14502"},{"key":"2400_CR43","doi-asserted-by":"crossref","unstructured":"Munari E, Rossi G, Zamboni G, Lunardi G, Marconi M, Sommaggio M, et al. PD-L1 Assays 22C3 and SP263 are Not Interchangeable in Non\u2013Small Cell Lung Cancer When Considering Clinically Relevant Cutoffs. Am J Surg Pathol . 2018;42:1384\u20139. Available from: https:\/\/journals.lww.com\/00000478-201810000-00012.","DOI":"10.1097\/PAS.0000000000001105"},{"key":"2400_CR44","doi-asserted-by":"crossref","unstructured":"Sholl LM, Aisner DL, Allen TC, Beasley MB, Borczuk AC, Cagle PT, et al. Programmed Death Ligand-1 Immunohistochemistry\u2014 A New Challenge for Pathologists: A Perspective From Members of the Pulmonary Pathology Society. Arch Pathol Lab Med . 2016;140:341\u20134. Available from: http:\/\/meridian.allenpress.com\/aplm\/article\/140\/4\/341\/65173\/Programmed-Death-Ligand1-Immunohistochemistry-A.","DOI":"10.5858\/arpa.2015-0506-SA"},{"key":"2400_CR45","doi-asserted-by":"crossref","unstructured":"Luchini C, Bibeau F, Ligtenberg MJL, Singh N, Nottegar A, Bosse T, et al. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1\/PD-L1 expression and tumour mutational burden: a systematic review-based approach. Ann Oncol . 2019;30:1232\u201343. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419312694.","DOI":"10.1093\/annonc\/mdz116"},{"key":"2400_CR46","doi-asserted-by":"crossref","unstructured":"Gennari A, Andr\u00e9 F, Barrios CH, Cort\u00e9s J, de Azambuja E, DeMichele A, et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol . 2021;32:1475\u201395. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753421044987.","DOI":"10.1016\/j.annonc.2021.09.019"},{"key":"2400_CR47","doi-asserted-by":"crossref","unstructured":"Adam J, Le Stang N, Rouquette I, Cazes A, Badoual C, Pinot-Roussel H, et al. Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer. Ann Oncol . 2018;29:953\u20138. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419454641.","DOI":"10.1093\/annonc\/mdy014"},{"key":"2400_CR48","doi-asserted-by":"crossref","unstructured":"Sholl LM, Awad M, Roy UB, Beasley MB, Cartun RW, Hwang DM, et al. Programmed death ligand-1 and tumor mutation burden testing of patients with lung cancer for selection of immune checkpoint inhibitor therapies. Arch Pathol Lab Med. 2024;148:757\u201374. Available from: https:\/\/www.cap.org\/member-resources\/articles\/cap-publishes-new-guideline-on-pd-l1-testing-of-patients-with-lung-cancer.","DOI":"10.5858\/arpa.2023-0536-CP"},{"key":"2400_CR49","doi-asserted-by":"crossref","unstructured":"Hirsch FR, McElhinny A, Stanforth D, Ranger-Moore J, Jansson M, Kulangara K, et al. PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project. J Thorac Oncol . 2017;12:208\u201322. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086416335365.","DOI":"10.1016\/j.jtho.2016.11.2228"},{"key":"2400_CR50","unstructured":"Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob J-J, Cowey CL, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017;377:1345\u201356. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/28889792\/."},{"key":"2400_CR51","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.18_suppl.LBA4","volume":"36","author":"G Lopes","year":"2018","unstructured":"Lopes G, Wu Y-L, Kudaba I, Kowalski D, Cho BC, Castro G, et al. Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced\/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) \u2265 1%: Open-label, phase 3 KEYNOTE-042 study. J Clin Oncol. 2018;36: LBA4\u2013LBA4.","journal-title":"J Clin Oncol"},{"key":"2400_CR52","doi-asserted-by":"crossref","unstructured":"Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379:2108\u201321. Available from: https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa1809615.","DOI":"10.1056\/NEJMoa1809615"},{"issue":"2","key":"2400_CR53","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1208\/s12248-021-00574-0","volume":"23","author":"JD Twomey","year":"2021","unstructured":"Twomey JD, Zhang B. Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics. AAPS J. 2021;23(2):39.","journal-title":"AAPS J"},{"key":"2400_CR54","doi-asserted-by":"crossref","unstructured":"Zhang T, Forde PM, Sullivan RJ, Sharon E, Barksdale E, Selig W, et al. Addressing resistance to PD-1\/PD-(L)1 pathway inhibition: considerations for combinatorial clinical trial designs. J Immunother Cancer. 2023;11:e006555. Available from: https:\/\/jitc.bmj.com\/content\/11\/5\/e006555.","DOI":"10.1136\/jitc-2022-006555"},{"key":"2400_CR55","doi-asserted-by":"crossref","unstructured":"Voutsadakis IA. High tumor mutation burden and other immunotherapy response predictors in breast cancers: associations and therapeutic opportunities. Target Oncol. 2020;15:127\u201338. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/31741177\/.","DOI":"10.1007\/s11523-019-00689-7"},{"key":"2400_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13000-020-00971-7","volume":"15","author":"P Mei","year":"2020","unstructured":"Mei P, Freitag CE, Wei L, Zhang Y, Parwani AV, Li Z. High tumor mutation burden is associated with DNA damage repair gene mutation in breast carcinomas. Diagn Pathol. 2020;15:1\u20137.","journal-title":"Diagn Pathol"},{"key":"2400_CR57","doi-asserted-by":"publisher","unstructured":"Takahashi H, Asaoka M, Yan L, Rashid OM, Oshi M, Ishikawa T, et al. Biologically Aggressive Phenotype and Anti-cancer Immunity Counterbalance in Breast Cancer with High Mutation Rate. Sci Rep . 2020;10:1\u201313. Available from: https:\/\/doi.org\/10.1038\/s41598-020-58995-4.","DOI":"10.1038\/s41598-020-58995-4"},{"key":"2400_CR58","doi-asserted-by":"crossref","unstructured":"McGranahan N, Furness AJS, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 2016;351:1463\u20139. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/26940869\/.","DOI":"10.1126\/science.aaf1490"},{"key":"2400_CR59","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/9056417","volume":"2019","author":"D Signorelli","year":"2019","unstructured":"Signorelli D, Giannatempo P, Grazia G, Aiello MM, Bertolini F, Mirabile A, et al. Patients selection for immunotherapy in solid tumors: overcome the na\u00efve vision of a single biomarker. Biomed Res Int. 2019;2019:9056417.","journal-title":"Biomed Res Int"},{"key":"2400_CR60","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","volume":"18","author":"MJ Overman","year":"2017","unstructured":"Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017;18:1182\u201391.","journal-title":"Lancet Oncol"},{"key":"2400_CR61","doi-asserted-by":"crossref","unstructured":"Marcus L, Lemery SJ, Keegan P, Pazdur R. FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors. Clin Cancer Res . 2019;25:3753\u20138. Available from: https:\/\/aacrjournals.org\/clincancerres\/article\/25\/13\/3753\/81631\/FDA-Approval-Summary-Pembrolizumab-for-the.","DOI":"10.1158\/1078-0432.CCR-18-4070"},{"key":"2400_CR62","doi-asserted-by":"crossref","unstructured":"Lin X, Zong C, Zhang Z, Fang W, Xu P. Progresses in biomarkers for cancer immunotherapy. MedComm. 2023;4. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/37799808\/.","DOI":"10.1002\/mco2.387"},{"key":"2400_CR63","doi-asserted-by":"crossref","unstructured":"Mok TSK, Lopes G, Cho BC, Kowalski DM, Kasahara K, Wu YL, et al. Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC. Ann Oncol. 2023;34:377\u201388. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/36709038\/.","DOI":"10.1016\/j.annonc.2023.01.011"},{"key":"2400_CR64","doi-asserted-by":"crossref","unstructured":"Ramalingam SS, Hellmann MD, Awad MM, Borghaei H, Gainor J, Brahmer J, et al. Abstract CT078: Tumor mutational burden (TMB) as a biomarker for clinical benefit from dual immune checkpoint blockade with nivolumab (nivo) + ipilimumab (ipi) in first-line (1L) non-small cell lung cancer (NSCLC): identification of TMB cutoff from CheckM. Cancer Res . 2018;78:CT078\u2013CT078. Available from: https:\/\/aacrjournals.org\/cancerres\/article\/78\/13_Supplement\/CT078\/631025\/Abstract-CT078-Tumor-mutational-burden-TMB-as-a.","DOI":"10.1158\/1538-7445.AM2018-CT078"},{"key":"2400_CR65","doi-asserted-by":"crossref","unstructured":"Yarchoan M, Hopkins A, Jaffee EM. Tumor Mutational Burden and Response Rate to PD-1 Inhibition. N Engl J Med . 2017;377:2500\u20131. Available from:http:\/\/www.nejm.org\/doi\/10.1056\/NEJMc1713444.","DOI":"10.1056\/NEJMc1713444"},{"key":"2400_CR66","doi-asserted-by":"crossref","unstructured":"Brown SD, Warren RL, Gibb EA, Martin SD, Spinelli JJ, Nelson BH, et al. Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. Genome Res. 2014;24:743\u201350. Available from: https:\/\/genome.cshlp.org\/content\/24\/5\/743.full.","DOI":"10.1101\/gr.165985.113"},{"key":"2400_CR67","doi-asserted-by":"crossref","unstructured":"Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N. Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity. Cell . 2015;160:48\u201361. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0092867414016390.","DOI":"10.1016\/j.cell.2014.12.033"},{"key":"2400_CR68","unstructured":"Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med . 2015;372:2509\u201320. Available from: http:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa1500596."},{"key":"2400_CR69","doi-asserted-by":"crossref","unstructured":"Hilmi M, Bartholin L, Neuzillet C. Immune therapies in pancreatic ductal adenocarcinoma: Where are we now? World J Gastroenterol . 2018;24:2137\u201351. Available from: http:\/\/www.wjgnet.com\/1007-9327\/full\/v24\/i20\/2137.htm.","DOI":"10.3748\/wjg.v24.i20.2137"},{"key":"2400_CR70","doi-asserted-by":"crossref","unstructured":"Cai Y, Gong M, Zeng M, Leng F, Lv D, Guo J, et al. Immunopeptidomics-guided discovery and characterization of neoantigens for personalized cancer immunotherapy. Sci Adv . 2025;11. Available from: https:\/\/www.science.org\/doi\/10.1126\/sciadv.adv6445.","DOI":"10.1126\/sciadv.adv6445"},{"key":"2400_CR71","doi-asserted-by":"crossref","unstructured":"Lu S, Stein JE, Rimm DL, Wang DW, Bell JM, Johnson DB, et al. Comparison of Biomarker Modalities for Predicting Response to PD-1\/PD-L1 Checkpoint Blockade. JAMA Oncol . 2019;5:1195. Available from: https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2738418.","DOI":"10.1001\/jamaoncol.2019.1549"},{"key":"2400_CR72","doi-asserted-by":"crossref","unstructured":"Taube JM, Akturk G, Angelo M, Engle EL, Gnjatic S, Greenbaum S, et al. The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation. J Immunother Cancer . 2020;8:e000155. Available from:https:\/\/www.jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2019-000155.","DOI":"10.1136\/jitc-2019-000155corr1"},{"key":"2400_CR73","doi-asserted-by":"crossref","unstructured":"Kuehn HS, Ouyang W, Lo B, Deenick EK, Niemela JE, Avery DT, et al. Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. Science (80- ) . 2014;345:1623\u20137. Available from: https:\/\/www.science.org\/doi\/10.1126\/science.1255904.","DOI":"10.1126\/science.1255904"},{"key":"2400_CR74","doi-asserted-by":"crossref","unstructured":"Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016:139\u201348. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/26765102\/.","DOI":"10.1016\/j.ejca.2015.11.016"},{"key":"2400_CR75","doi-asserted-by":"crossref","unstructured":"Choi J, Lee SY. Clinical Characteristics and Treatment of Immune-Related Adverse Events of Immune Checkpoint Inhibitors. Immune Netw . 2020;20. Available from: https:\/\/immunenetwork.org\/x.php?id=10.4110\/in.2020.20.e9.","DOI":"10.4110\/in.2020.20.e9"},{"key":"2400_CR76","doi-asserted-by":"crossref","unstructured":"Kong Y, Hong L, Xu XC, Chen YF, Xu J. The relative risk of immune checkpoint inhibitor pneumonitis in advanced non-small- cell lung cancer: meta-analyses of controlled clinical trials. PLoS One. 2024;19:e0301931. Available from: https:\/\/journals.plos.org\/plosone\/article?id=10.1371\/journal.pone.0301931.","DOI":"10.1371\/journal.pone.0301931"},{"key":"2400_CR77","doi-asserted-by":"crossref","unstructured":"Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol . 2019 [cited 2024 Apr 15];16:563\u201380. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/31092901\/.","DOI":"10.1038\/s41571-019-0218-0"},{"key":"2400_CR78","doi-asserted-by":"crossref","unstructured":"Verheijden RJ, van Eijs MJM, May AM, van Wijk F, Suijkerbuijk KPM. Immunosuppression for immune-related adverse events during checkpoint inhibition: an intricate balance. npj Precis Oncol . 2023;7:41. Available from: https:\/\/www.nature.com\/articles\/s41698-023-00380-1.","DOI":"10.1038\/s41698-023-00380-1"},{"key":"2400_CR79","doi-asserted-by":"crossref","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021;39:4073\u2013126. Available from: https:\/\/www.ascopubs.org\/doi\/10.1200\/JCO.21.01440.","DOI":"10.1200\/JCO.21.01440"},{"key":"2400_CR80","doi-asserted-by":"crossref","unstructured":"Sun JY, Zhang D, Wu S, Xu M, Zhou X, Lu XJ, et al. Resistance to PD-1\/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives. Biomark. Res. BioMed Central. 2020:1\u201310. Available from: https:\/\/biomarkerres.biomedcentral.com\/articles\/10.1186\/s40364-020-00212-5.","DOI":"10.1186\/s40364-020-00212-5"},{"key":"2400_CR81","doi-asserted-by":"crossref","unstructured":"Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, Adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017:707\u201323. Available from: hnih.gov\/28187290ttps:\/\/pubmed.ncbi.nlm.\/.","DOI":"10.1016\/j.cell.2017.01.017"},{"issue":"9","key":"2400_CR82","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.trecan.2021.03.003","volume":"7","author":"W Xiong","year":"2021","unstructured":"Xiong W, Gao Y, Wei W, Zhang J. Extracellular and nuclear PD-L1 in modulating cancer immunotherapy. Trends Cancer. 2021;7(9):837\u201346.","journal-title":"Trends Cancer"},{"key":"2400_CR83","doi-asserted-by":"crossref","unstructured":"Kim JM, Chen DS. Immune escape to PD-L1\/PD-1 blockade: seven steps to success (or failure). Ann Oncol . 2016;27:1492\u2013504. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419347465.","DOI":"10.1093\/annonc\/mdw217"},{"key":"2400_CR84","doi-asserted-by":"crossref","unstructured":"Zhang J, Dang F, Ren J, Wei W. Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy . Trends Biochem. Sci. 2018. p. 1014\u201332. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968000418301877.","DOI":"10.1016\/j.tibs.2018.09.004"},{"key":"2400_CR85","doi-asserted-by":"crossref","unstructured":"Wang Y, Wang H, Yao H, Li C, Fang J-YY, Xu J, et al. Regulation of PD-L1: emerging routes for targeting tumor immune evasion. Front Pharmacol. 2018;9:536. Available from: https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2018.00536\/full.","DOI":"10.3389\/fphar.2018.00536"},{"key":"2400_CR86","unstructured":"Han Y, Liu D, Li L. PD-1\/PD-L1 pathway: current researches in cancer. Am J Cancer Res . 2020;10:727\u201342. Available from: www.ajcr.us\/."},{"key":"2400_CR87","doi-asserted-by":"crossref","unstructured":"Haupt S, Caramia F, Klein SL, Rubin JB, Haupt Y. Sex disparities matter in cancer development and therapy. Nat Rev Cancer . 2021;21:393\u2013407. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/33879867.","DOI":"10.1038\/s41568-021-00348-y"},{"key":"2400_CR88","doi-asserted-by":"crossref","unstructured":"Sahay O, Barik GK, Islam S. FBXW10: a male-biased E3 ligase in liver cancer. Trends in cancer . 2023;9:876\u20138. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/37775405.","DOI":"10.1016\/j.trecan.2023.09.004"},{"key":"2400_CR89","doi-asserted-by":"crossref","unstructured":"Cook MB, McGlynn KA, Devesa SS, Freedman ND, Anderson WF. Sex Disparities in Cancer Mortality and Survival. Cancer Epidemiol Biomarkers Prev . 2011;20:1629\u201337. Available from: https:\/\/aacrjournals.org\/cebp\/article\/20\/8\/1629\/69017\/Sex-Disparities-in-Cancer-Mortality-and.","DOI":"10.1158\/1055-9965.EPI-11-0246"},{"key":"2400_CR90","doi-asserted-by":"crossref","unstructured":"Conforti F, Pala L, Di Mitri D, Catania C, Cocorocchio E, Laszlo D, et al. Sex hormones, the anticancer immune response, and therapeutic opportunities. Cancer Cell . 2025;43:343\u201360. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1535610825000650.","DOI":"10.1016\/j.ccell.2025.02.013"},{"key":"2400_CR91","doi-asserted-by":"crossref","unstructured":"Ye Y, Jing Y, Li L, Mills GB, Diao L, Liu H, et al. Sex-associated molecular differences for cancer immunotherapy. Nat Commun . 2020;11:1779. Available from: https:\/\/www.nature.com\/articles\/s41467-020-15679-x.","DOI":"10.1038\/s41467-020-15679-x"},{"key":"2400_CR92","doi-asserted-by":"crossref","unstructured":"Conforti F, Pala L, Bagnardi V, De Pas T, Martinetti M, Viale G, et al. Cancer immunotherapy efficacy and patients\u2019 sex: a systematic review and meta-analysis. Lancet Oncol . 2018;19:737\u201346. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1470204518302614.","DOI":"10.1016\/S1470-2045(18)30261-4"},{"key":"2400_CR93","doi-asserted-by":"crossref","unstructured":"Ye Y, Jing Y, Li L, Mills GB, Diao L, Liu H, et al. Sex-associated molecular differences for cancer immunotherapy. Nat Commun . 2020;11:1779. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32286310.","DOI":"10.1038\/s41467-020-15679-x"},{"key":"2400_CR94","doi-asserted-by":"crossref","unstructured":"Pala L, De Pas T, Catania C, Giaccone G, Mantovani A, Minucci S, et al. Sex and cancer immunotherapy: Current understanding and challenges. Cancer Cell . 2022;40:695\u2013700. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/35750053.","DOI":"10.1016\/j.ccell.2022.06.005"},{"key":"2400_CR95","doi-asserted-by":"crossref","unstructured":"Dunford A, Weinstock DM, Savova V, Schumacher SE, Cleary JP, Yoda A, et al. Tumor-suppressor genes that escape from X-inactivation contribute to cancer sex bias. Nat Genet . 2017;49:10\u20136. Available from: https:\/\/www.nature.com\/articles\/ng.3726.","DOI":"10.1038\/ng.3726"},{"key":"2400_CR96","doi-asserted-by":"crossref","unstructured":"Xiao T, Lee J, Gauntner TD, Velegraki M, Lathia JD, Li Z. Hallmarks of sex bias in immuno-oncology: mechanisms and therapeutic implications. Nat Rev Cancer . 2024;24:338\u201355. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/38589557.","DOI":"10.1038\/s41568-024-00680-z"},{"key":"2400_CR97","doi-asserted-by":"crossref","unstructured":"Yang L, Huang F, Mei J, Wang X, Zhang Q, Wang H, et al. Posttranscriptional Control of PD-L1 Expression by 17\u03b2-Estradiol via PI3K\/Akt Signaling Pathway in ER\u03b1-Positive Cancer Cell Lines. Int J Gynecol Cancer . 2017;27:196\u2013205. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X2404338X.","DOI":"10.1097\/IGC.0000000000000875"},{"key":"2400_CR98","doi-asserted-by":"crossref","unstructured":"Lindblad KE, Donne R, Liebling I, Barcena-Varela M, Lozano A, Ruiz de Galarreta M, et al. NOTCH1 Drives Sexually Dimorphic Immune Responses in Hepatocellular Carcinoma. Cancer Discov . 2025;15:495\u2013510. Available from: https:\/\/aacrjournals.org\/cancerdiscovery\/article\/15\/3\/495\/752120\/NOTCH1-Drives-Sexually-Dimorphic-Immune-Responses.","DOI":"10.1158\/2159-8290.CD-24-1215"},{"key":"2400_CR99","unstructured":"Chen X, Shen Y, Choi S, Abdel-Hafiz HA, Basu M, Hoelzen L, et al. Concurrent loss of the Y chromosome in cancer and T cells impacts outcome. Nature . 2025; Available from: https:\/\/www.nature.com\/articles\/s41586-025-09071-2."},{"key":"2400_CR100","unstructured":"Zhu Q, Zhang G, Cao M, Huang H, He D, Zang Z, et al. Microbiota-shaped neutrophil senescence regulates sexual dimorphism in bladder cancer. Nat Immunol . 2025; Available from: https:\/\/www.nature.com\/articles\/s41590-025-02126-6."},{"issue":"11","key":"2400_CR101","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1001\/jamaoncol.2016.2450","volume":"2","author":"Y Zhang","year":"2016","unstructured":"Zhang Y, Chen L. Classification of advanced human cancers based on tumor immunity in the microenvironment (TIME) for cancer immunotherapy. JAMA Oncol. 2016;2:1403. https:\/\/doi.org\/10.1001\/jamaoncol.2016.2450.","journal-title":"JAMA Oncol"},{"key":"2400_CR102","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168:707\u201323. https:\/\/doi.org\/10.1016\/j.cell.2017.01.017.","journal-title":"Cell"},{"key":"2400_CR103","doi-asserted-by":"crossref","unstructured":"Kluger H, Barrett JC, Gainor JF, Hamid O, Hurwitz M, LaVallee T, et al. Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors. J Immunother Cancer . 2023;11:e005921. Available from: https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2022-005921.","DOI":"10.1136\/jitc-2022-005921"},{"key":"2400_CR104","doi-asserted-by":"crossref","unstructured":"Shirasawa M, Yoshida T, Shimoda Y, Takayanagi D, Shiraishi K, Kubo T, et al. Differential immune-related microenvironment determines programmed cell death protein-1\/programmed death-ligand 1 blockade efficacy in patients with advanced NSCLC. J Thorac Oncol. 2021;16:2078\u201390. Available from: http:\/\/www.jto.org\/article\/S155608642102373X\/fulltext.","DOI":"10.1016\/j.jtho.2021.07.027"},{"key":"2400_CR105","doi-asserted-by":"crossref","unstructured":"Sun D, Liu J, Zhou H, Shi M, Sun J, Zhao S, et al. Classification of tumor immune microenvironment according to programmed death-ligand 1 expression and immune infiltration predicts response to immunotherapy plus chemotherapy in advanced patients with NSCLC. J Thorac Oncol. 2023;18:869\u201381. Available from: http:\/\/www.jto.org\/article\/S1556086423001946\/fulltext.","DOI":"10.1016\/j.jtho.2023.03.012"},{"key":"2400_CR106","doi-asserted-by":"crossref","unstructured":"Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci Transl Med . 2016;8. Available from: https:\/\/www.science.org\/doi\/10.1126\/scitranslmed.aad7118.","DOI":"10.1126\/scitranslmed.aad7118"},{"key":"2400_CR107","doi-asserted-by":"crossref","unstructured":"Shin DS, Zaretsky JM, Escuin-Ordinas H, Garcia-Diaz A, Hu-Lieskovan S, Kalbasi A, et al. Primary Resistance to PD-1 Blockade Mediated by JAK1\/2 Mutations. Cancer Discov . 2017;7:188\u2013201. Available from: https:\/\/aacrjournals.org\/cancerdiscovery\/article\/7\/2\/188\/6004\/Primary-Resistance-to-PD-1-Blockade-Mediated-by.","DOI":"10.1158\/2159-8290.CD-16-1223"},{"key":"2400_CR108","doi-asserted-by":"crossref","unstructured":"Aust S, Felix S, Auer K, Bachmayr-Heyda A, Kenner L, Dekan S, et al. Absence of PD-L1 on tumor cells is associated with reduced MHC I expression and PD-L1 expression increases in recurrent serous ovarian cancer. Sci Rep . 2017;7:42929. Available from: https:\/\/www.nature.com\/articles\/srep42929.","DOI":"10.1038\/srep42929"},{"key":"2400_CR109","doi-asserted-by":"crossref","unstructured":"Vesely MD, Zhang T, Chen L. Resistance mechanisms to anti-pd cancer immunotherapy. Annu Rev Immunol. 2022;40:45\u201374. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/35471840\/.","DOI":"10.1146\/annurev-immunol-070621-030155"},{"key":"2400_CR110","doi-asserted-by":"publisher","first-page":"5553","DOI":"10.1172\/JCI129025","volume":"129","author":"DK Nambiar","year":"2019","unstructured":"Nambiar DK, Aguilera T, Cao H, Kwok S, Kong C, Bloomstein J, et al. Galectin-1-driven T cell exclusion in the tumor endothelium promotes immunotherapy resistance. J Clin Invest. 2019;129:5553\u201367.","journal-title":"J Clin Invest"},{"key":"2400_CR111","unstructured":"Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, et al. Loss of PTEN Promotes Resistance to T Cell\u2013Mediated Immunotherapy. Cancer Discov . 2016;6:202\u201316. Available from: https:\/\/aacrjournals.org\/cancerdiscovery\/article\/6\/2\/202\/5350\/Loss-of-PTEN-Promotes-Resistance-to-T-Cell."},{"key":"2400_CR112","unstructured":"Jerby-Arnon L, Shah P, Cuoco MS, Rodman C, Su M-J, Melms JC, et al. A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade. Cell . 2018;175:984\u2013997.e24. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0092867418311784."},{"key":"2400_CR113","doi-asserted-by":"crossref","unstructured":"Aaltomaa S, Lipponen P, Eskelinen M, Kosma V-M, Marin S, Alhava E, et al. Lymphocyte infiltrates as a prognostic variable in female breast cancer. Eur J Cancer . 1992;28:859\u201364. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/095980499290134N.","DOI":"10.1016\/0959-8049(92)90134-N"},{"key":"2400_CR114","doi-asserted-by":"crossref","unstructured":"Savas P, Salgado R, Denkert C, Sotiriou C, Darcy PK, Smyth MJ, et al. Clinical relevance of host immunity in breast cancer: from TILs to the clinic. Nat Rev Clin Oncol . 2016;13:228\u201341. Available from: https:\/\/www.nature.com\/articles\/nrclinonc.2015.215.","DOI":"10.1038\/nrclinonc.2015.215"},{"key":"2400_CR115","doi-asserted-by":"crossref","unstructured":"Samstein RM, Lee C-H, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet . 2019;51:202\u20136. Available from: https:\/\/www.nature.com\/articles\/s41588-018-0312-8.","DOI":"10.1038\/s41588-018-0312-8"},{"key":"2400_CR116","doi-asserted-by":"crossref","unstructured":"Denkert C, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner BI, Weber KE, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol . 2018;19:40\u201350. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S147020451730904X.","DOI":"10.1016\/S1470-2045(17)30904-X"},{"key":"2400_CR117","doi-asserted-by":"publisher","unstructured":"Goldberg J, Pastorello RG, Vallius T, Davis J, Cui YX, Agudo J, et al. The Immunology of Hormone Receptor Positive Breast Cancer. Front Immunol . 2021;12. Available from:https:\/\/www.frontiersin.org\/articles\/https:\/\/doi.org\/10.3389\/fimmu.2021.674192\/full.","DOI":"10.3389\/fimmu.2021.674192\/full"},{"key":"2400_CR118","doi-asserted-by":"publisher","first-page":"14872","DOI":"10.1080\/21655979.2022.2162660","volume":"13","author":"M Qin","year":"2022","unstructured":"Qin M, Chen G, Hou J, Wang L, Wang Q, Wang L, et al. Tumor-infiltrating lymphocyte: features and prognosis of lymphocytes infiltration on colorectal cancer. Bioengineered. 2022;13:14872\u201388. https:\/\/doi.org\/10.1080\/21655979.2022.2162660.","journal-title":"Bioengineered"},{"key":"2400_CR119","doi-asserted-by":"crossref","unstructured":"Koch M, Beckhove P, op den Winkel J, Autenrieth D, Wagner P, Nummer D, et al. Tumor Infiltrating T Lymphocytes in Colorectal Cancer. Ann Surg . 2006;244:986\u201393. Available from: http:\/\/journals.lww.com\/00000658-200612000-00019.","DOI":"10.1097\/01.sla.0000247058.43243.7b"},{"key":"2400_CR120","doi-asserted-by":"crossref","unstructured":"Lim Y, Choi S, Oh HJ, Kim C, Song S, Kim S, et al. Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes for prediction of prognosis in resected colon cancer. npj Precis Oncol . 2023;7:124. Available from: https:\/\/www.nature.com\/articles\/s41698-023-00470-0.","DOI":"10.1038\/s41698-023-00470-0"},{"key":"2400_CR121","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1158\/0008-5472.CAN-19-3158","volume":"80","author":"K Ford","year":"2020","unstructured":"Ford K, Hanley CJ, Mellone M, Szyndralewiez C, Heitz F, Wiesel P, et al. NOX4 inhibition potentiates immunotherapy by overcoming cancer-associated fibroblast-mediated CD8 T-cell exclusion from tumors. Cancer Res. 2020;80:1846\u201360.","journal-title":"Cancer Res"},{"key":"2400_CR122","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1158\/2326-6066.CIR-19-0349","volume":"8","author":"B Mirlekar","year":"2020","unstructured":"Mirlekar B, Michaud D, Lee SJ, Kren NP, Harris C, Greene K, et al. Bcell-derived IL35 drives STAT3-DependentCD8+ T-cell exclusion in pancreatic cancer. Cancer Immunol Res. 2020;8:292\u2013308.","journal-title":"Cancer Immunol Res"},{"key":"2400_CR123","doi-asserted-by":"crossref","unstructured":"Ding X, Wang L, Zhang X, Xu J, Li P, Liang H, et al. The relationship between expression of PD-L1 and HIF-1\u03b1 in glioma cells under hypoxia. J Hematol Oncol . 2021;14:92. Available from: https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-021-01102-5.","DOI":"10.1186\/s13045-021-01102-5"},{"key":"2400_CR124","doi-asserted-by":"crossref","unstructured":"Chen Z, Han F, Du Y, Shi H, Zhou W. Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions. Signal Transduct Target Ther . 2023;8:70. Available from: https:\/\/www.nature.com\/articles\/s41392-023-01332-8.","DOI":"10.1038\/s41392-023-01332-8"},{"key":"2400_CR125","doi-asserted-by":"crossref","unstructured":"Calcinotto A, Filipazzi P, Grioni M, Iero M, De Milito A, Ricupito A, et al. Modulation of Microenvironment Acidity Reverses Anergy in Human and Murine Tumor-Infiltrating T Lymphocytes. Cancer Res . 2012;72:2746\u201356. Available from: https:\/\/aacrjournals.org\/cancerres\/article\/72\/11\/2746\/575694\/Modulation-of-Microenvironment-Acidity-Reverses.","DOI":"10.1158\/0008-5472.CAN-11-1272"},{"key":"2400_CR126","unstructured":"Arce Vargas F, Furness AJS, Solomon I, Joshi K, Mekkaoui L, Lesko MH, et al. Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors. Immunity . 2017;46:577\u201386. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1074761317301231."},{"key":"2400_CR127","doi-asserted-by":"crossref","unstructured":"Shang B, Liu Y, Jiang S, Liu Y. Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis. Sci Rep . 2015;5:15179. Available from: https:\/\/www.nature.com\/articles\/srep15179.","DOI":"10.1038\/srep15179"},{"key":"2400_CR128","doi-asserted-by":"crossref","unstructured":"Veglia F, Perego M, Gabrilovich D. Myeloid-derived suppressor cells coming of age. Nat Immunol . 2018;19:108\u201319. Available from: https:\/\/www.nature.com\/articles\/s41590-017-0022-x.","DOI":"10.1038\/s41590-017-0022-x"},{"key":"2400_CR129","doi-asserted-by":"crossref","unstructured":"Weide B, Martens A, Zelba H, Stutz C, Derhovanessian E, Di Giacomo AM, et al. Myeloid-Derived Suppressor Cells Predict Survival of Patients with Advanced Melanoma: Comparison with Regulatory T Cells and NY-ESO-1- or Melan-A\u2013Specific T Cells. Clin Cancer Res . 2014;20:1601\u20139. Available from: https:\/\/aacrjournals.org\/clincancerres\/article\/20\/6\/1601\/212176\/Myeloid-Derived-Suppressor-Cells-Predict-Survival.","DOI":"10.1158\/1078-0432.CCR-13-2508"},{"key":"2400_CR130","doi-asserted-by":"crossref","unstructured":"Srivastava MK, Sinha P, Clements VK, Rodriguez P, Ostrand-Rosenberg S. Myeloid-Derived Suppressor Cells Inhibit T-Cell Activation by Depleting Cystine and Cysteine. Cancer Res . 2010;70:68\u201377. Available from: https:\/\/aacrjournals.org\/cancerres\/article\/70\/1\/68\/559638\/Myeloid-Derived-Suppressor-Cells-Inhibit-T-Cell.","DOI":"10.1158\/0008-5472.CAN-09-2587"},{"key":"2400_CR131","doi-asserted-by":"crossref","unstructured":"Rodriguez PC, Quiceno DG, Zabaleta J, Ortiz B, Zea AH, Piazuelo MB, et al. Arginase I Production in the Tumor Microenvironment by Mature Myeloid Cells Inhibits T-Cell Receptor Expression and Antigen-Specific T-Cell Responses. Cancer Res . 2004;64:5839\u201349. Available from: https:\/\/aacrjournals.org\/cancerres\/article\/64\/16\/5839\/511544\/Arginase-I-Production-in-the-Tumor.","DOI":"10.1158\/0008-5472.CAN-04-0465"},{"key":"2400_CR132","doi-asserted-by":"crossref","unstructured":"Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med . 2004;10:942\u20139. Available from: https:\/\/www.nature.com\/articles\/nm1093.","DOI":"10.1038\/nm1093"},{"key":"2400_CR133","doi-asserted-by":"crossref","unstructured":"Ciarka A, Pi\u0105tek M, P\u0119ksa R, Kunc M, Senkus E. Tumor-Infiltrating Lymphocytes (TILs) in Breast Cancer: Prognostic and Predictive Significance across Molecular Subtypes. Biomedicines . 2024;12:763. Available from: https:\/\/www.mdpi.com\/2227-9059\/12\/4\/763.","DOI":"10.3390\/biomedicines12040763"},{"key":"2400_CR134","doi-asserted-by":"crossref","unstructured":"Kallingal A, Olszewski M, Maciejewska N, Brankiewicz W, Baginski M. Cancer immune escape: the role of antigen presentation machinery. J Cancer Res Clin Oncol . 2023;149:8131\u201341. Available from: https:\/\/www.link.springer.com\/10.1007\/s00432-023-04737-8.","DOI":"10.1007\/s00432-023-04737-8"},{"key":"2400_CR135","doi-asserted-by":"crossref","unstructured":"Sade-Feldman M, Jiao YJ, Chen JH, Rooney MS, Barzily-Rokni M, Eliane J-P, et al. Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nat Commun . 2017;8:1136. Available from: https:\/\/www.nature.com\/articles\/s41467-017-01062-w.","DOI":"10.1038\/s41467-017-01062-w"},{"key":"2400_CR136","doi-asserted-by":"crossref","unstructured":"Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med. 2016;375:819\u201329. Available from: https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa1604958.","DOI":"10.1056\/NEJMoa1604958"},{"key":"2400_CR137","doi-asserted-by":"crossref","unstructured":"Gettinger S, Choi J, Hastings K, Truini A, Datar I, Sowell R, et al. Impaired HLA Class I Antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer. Cancer Discov. 2017;7:1420\u201335. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/29025772\/.","DOI":"10.1158\/2159-8290.CD-17-0593"},{"key":"2400_CR138","doi-asserted-by":"publisher","DOI":"10.1038\/s44321-025-00213-7","author":"RP Deshpande","year":"2025","unstructured":"Deshpande RP, Wu K, Wu SY, Tyagi A, Smith EC, Kim JW, et al. MHC-I upregulation by macbecin II in the solid tumors potentiates the effect of active immunotherapy. EMBO Mol Med. 2025. https:\/\/doi.org\/10.1038\/s44321-025-00213-7.","journal-title":"EMBO Mol Med"},{"key":"2400_CR139","doi-asserted-by":"crossref","unstructured":"Chesner LN, Polesso F, Graff JN, Hawley JE, Smith AK, Lundberg A, et al. Androgen Receptor Inhibition Increases MHC Class I Expression and Improves Immune Response in Prostate Cancer. Cancer Discov . 2025;15:481\u201394. Available from: https:\/\/aacrjournals.org\/cancerdiscovery\/article\/15\/3\/481\/752114\/Androgen-Receptor-Inhibition-Increases-MHC-Class-I.","DOI":"10.1158\/2159-8290.CD-24-0559"},{"key":"2400_CR140","doi-asserted-by":"crossref","unstructured":"Rock KL, Gramm C, Rothstein L, Clark K, Stein R, Dick L, et al. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell . 1994;78:761\u201371. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0092867494904626.","DOI":"10.1016\/S0092-8674(94)90462-6"},{"key":"2400_CR141","doi-asserted-by":"crossref","unstructured":"Ling A, L\u00f6fgren-Burstr\u00f6m A, Larsson P, Li X, Wikberg ML, \u00d6berg \u00c5, et al. TAP1 down-regulation elicits immune escape and poor prognosis in colorectal cancer. Oncoimmunology . 2017;6:e1356143. Available from: https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/2162402X.2017.1356143.","DOI":"10.1080\/2162402X.2017.1356143"},{"key":"2400_CR142","doi-asserted-by":"crossref","unstructured":"Tu Z, Li K, Ji Q, Huang Y, Lv S, Li J, et al. Pan-cancer analysis: predictive role of TAP1 in cancer prognosis and response to immunotherapy. BMC Cancer . 2023;23:133. Available from: https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-022-10491-w.","DOI":"10.1186\/s12885-022-10491-w"},{"key":"2400_CR143","doi-asserted-by":"crossref","unstructured":"Tabassum A, Samdani MN, Dhali TC, Alam R, Ahammad F, Samad A, et al. Transporter associated with antigen processing 1 (TAP1) expression and prognostic analysis in breast, lung, liver, and ovarian cancer. J Mol Med . 2021;99:1293\u2013309. Available from: https:\/\/link.springer.com\/10.1007\/s00109-021-02088-w.","DOI":"10.1007\/s00109-021-02088-w"},{"key":"2400_CR144","doi-asserted-by":"crossref","unstructured":"Shionoya Y, Kanaseki T, Miyamoto S, Tokita S, Hongo A, Kikuchi Y, et al. Loss of tapasin in human lung and colon cancer cells and escape from tumor-associated antigen-specific CTL recognition. Oncoimmunology . 2017;6:e1274476. Available from: https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/2162402X.2016.1274476.","DOI":"10.1080\/2162402X.2016.1274476"},{"key":"2400_CR145","doi-asserted-by":"crossref","unstructured":"Sokol L, Koelzer VH, Rau TT, Karamitopoulou E, Zlobec I, Lugli A. Loss of tapasin correlates with diminished CD8+ T-cell immunity and prognosis in colorectal cancer. J Transl Med . 2015;13:279. Available from: http:\/\/www.translational-medicine.com\/content\/13\/1\/279.","DOI":"10.1186\/s12967-015-0647-1"},{"key":"2400_CR146","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1007\/s00262-008-0515-4","volume":"57","author":"B Seliger","year":"2008","unstructured":"Seliger B. Molecular mechanisms of MHC class I abnormalities and APM components in human tumors. Cancer Immunol Immunother. 2008;57:1719\u201326.","journal-title":"Cancer Immunol Immunother"},{"key":"2400_CR147","doi-asserted-by":"crossref","unstructured":"Lee MY, Jeon JW, Sievers C, Allen CT. Antigen processing and presentation in cancer immunotherapy. J Immunother Cancer . 2020;8:e001111. Available from: https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2020-001111.","DOI":"10.1136\/jitc-2020-001111"},{"key":"2400_CR148","doi-asserted-by":"crossref","unstructured":"Zhou X, Sun S-C. Targeting ubiquitin signaling for cancer immunotherapy. Signal Transduct Target Ther . 2021;6:16. Available from: https:\/\/www.nature.com\/articles\/s41392-020-00421-2.","DOI":"10.1038\/s41392-020-00421-2"},{"key":"2400_CR149","doi-asserted-by":"crossref","unstructured":"Zhang Z, Sie B, Chang A, Leng Y, Nardone C, Timms RT, et al. Elucidation of E3 ubiquitin ligase specificity through proteome-wide internal degron mapping. Mol Cell . 2023;83:3377\u20133392.e6. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1097276523006585.","DOI":"10.1016\/j.molcel.2023.08.022"},{"key":"2400_CR150","doi-asserted-by":"crossref","unstructured":"Jaeger AM, Stopfer LE, Ahn R, Sanders EA, Sandel DA, Freed-Pastor WA, et al. Deciphering the immunopeptidome in vivo reveals new tumour antigens. Nature . 2022;607:149\u201355. Available from: https:\/\/www.nature.com\/articles\/s41586-022-04839-2.","DOI":"10.1038\/s41586-022-04839-2"},{"key":"2400_CR151","doi-asserted-by":"crossref","unstructured":"Tang T, Huang X, Zhang G, Hong Z, Bai X, Liang T. Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy. Signal Transduct Target Ther . 2021;6:72. Available from: https:\/\/www.nature.com\/articles\/s41392-020-00449-4.","DOI":"10.1038\/s41392-020-00449-4"},{"key":"2400_CR152","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/15384047.2017.1394538","volume":"19","author":"H Patel","year":"2018","unstructured":"Patel H, Nilendu P, Jahagirdar D, Pal JK, Sharma NK. Modulating secreted components of tumor microenvironment: a masterstroke in tumor therapeutics. Cancer Biol Ther. 2018;19:3\u201312. https:\/\/doi.org\/10.1080\/15384047.2017.1394538.","journal-title":"Cancer Biol Ther"},{"issue":"5","key":"2400_CR153","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1002\/cac2.12539","volume":"44","author":"GR Khosravi","year":"2024","unstructured":"Khosravi GR, Mostafavi S, Bastan S, Ebrahimi N, Gharibvand RS, Eskandari N. Immunologic tumor microenvironment modulators for turning cold tumors hot. Cancer Commun. 2024;44(5):521\u201353.","journal-title":"Cancer Commun."},{"key":"2400_CR154","doi-asserted-by":"crossref","unstructured":"Ma K, Wang L, Li W, Tang T, Ma B, Zhang L, et al. Turning cold into hot: emerging strategies to fire up the tumor microenvironment. Trends in Cancer . 2025;11:117\u201334. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405803324002784.","DOI":"10.1016\/j.trecan.2024.11.011"},{"key":"2400_CR155","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-024-01990-4","volume":"23","author":"M Kundu","year":"2024","unstructured":"Kundu M, Butti R, Panda VK, Malhotra D, Das S, Mitra T, et al. Modulation of the tumor microenvironment and mechanism of immunotherapy-based drug resistance in breast cancer. Mol Cancer. 2024;23:1\u201327.","journal-title":"Mol Cancer"},{"key":"2400_CR156","doi-asserted-by":"crossref","unstructured":"Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol . 2017;14:399\u2013416. Available from: https:\/\/www.nature.com\/articles\/nrclinonc.2016.217.","DOI":"10.1038\/nrclinonc.2016.217"},{"key":"2400_CR157","doi-asserted-by":"crossref","unstructured":"Lamorte S, Quevedo R, Jin R, Neufeld L, Liu ZQ, Ciudad MT, et al. Lymph node macrophages drive immune tolerance and resistance to cancer therapy by induction of the immune-regulatory cytokine IL-33. Cancer Cell . 2025; Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1535610825000698.","DOI":"10.1016\/j.ccell.2025.02.017"},{"key":"2400_CR158","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1016\/j.bbamcr.2014.05.014","volume":"1843","author":"MD Turner","year":"2014","unstructured":"Turner MD, Nedjai B, Hurst T, Pennington DJ. Cytokines and chemokines: at the crossroads of cell signalling and inflammatory disease. Biochim Biophys Acta-Mol Cell Res. 2014;1843:2563\u201382.","journal-title":"Biochim Biophys Acta-Mol Cell Res"},{"key":"2400_CR159","doi-asserted-by":"crossref","unstructured":"Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, et al. TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nat. 2018;554:544\u20138. Available from: https:\/\/www.nature.com\/articles\/nature25501.","DOI":"10.1038\/nature25501"},{"key":"2400_CR160","doi-asserted-by":"publisher","first-page":"5265","DOI":"10.7150\/thno.58390","volume":"11","author":"YT Liu","year":"2021","unstructured":"Liu YT, Sun ZJ. Turning cold tumors into hot tumors by improving T-cell infiltration. Theranostics. 2021;11:5265\u201386","journal-title":"Theranostics"},{"key":"2400_CR161","doi-asserted-by":"crossref","unstructured":"Tauriello DVF, Palomo-Ponce S, Stork D, Berenguer-Llergo A, Badia-Ramentol J, Iglesias M, et al. TGF\u03b2 drives immune evasion in genetically reconstituted colon cancer metastasis. Nature . 2018;554:538\u201343. Available from: https:\/\/www.nature.com\/articles\/nature25492.","DOI":"10.1038\/nature25492"},{"key":"2400_CR162","doi-asserted-by":"crossref","unstructured":"Hanks BA, Holtzhausen A, Evans KS, Jamieson R, Gimpel P, Campbell OM, et al. Type III TGF-\u03b2 receptor downregulation generates an immunotolerant tumor microenvironment. J Clin Invest . 2013;123:3925\u201340. Available from: http:\/\/www.jci.org\/articles\/view\/65745.","DOI":"10.1172\/JCI65745"},{"key":"2400_CR163","doi-asserted-by":"crossref","unstructured":"Lan Y, Moustafa M, Knoll M, Xu C, Furkel J, Lazorchak A, et al. Simultaneous targeting of TGF-\u03b2\/PD-L1 synergizes with radiotherapy by reprogramming the tumor microenvironment to overcome immune evasion. Cancer Cell . 2021;39:1388\u20131403.e10. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34506739.","DOI":"10.1016\/j.ccell.2021.08.008"},{"key":"2400_CR164","unstructured":"Castiglioni A, Yang Y, Williams K, Gogineni A, Lane RS, Wang AW, et al. Combined PD-L1\/TGF\u03b2 blockade allows expansion and differentiation of stem cell-like CD8 T cells in immune excluded tumors. Nat Commun . 2023;14:4703. Available from: https:\/\/www.nature.com\/articles\/s41467-023-40398-4."},{"key":"2400_CR165","doi-asserted-by":"crossref","unstructured":"Kang J, Jung M, Choudhury M, Leof EB. Transforming growth factor beta induces fibroblasts to express and release the immunomodulatory protein PD\u2010L1 into extracellular vesicles. FASEB J . 2020;34:2213\u201326. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/10.1096\/fj.201902354R.","DOI":"10.1096\/fj.201902354R"},{"key":"2400_CR166","doi-asserted-by":"crossref","unstructured":"Rodriguez-Baena FJ, Marquez-Galera A, Ballesteros-Martinez P, Castillo A, Diaz E, Moreno-Bueno G, et al. Microglial reprogramming enhances antitumor immunity and immunotherapy response in melanoma brain metastases. Cancer Cell . 2025;43:413\u2013427.e9. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1535610825000261.","DOI":"10.1016\/j.ccell.2025.01.008"},{"key":"2400_CR167","doi-asserted-by":"crossref","unstructured":"Bonaventura P, Shekarian T, Alcazer V, Valladeau-Guilemond J, Valsesia-Wittmann S, Amigorena S, et al. Cold tumors: a therapeutic challenge for immunotherapy. Front Immunol. 2019;10:440886. Available from: www.frontiersin.org.","DOI":"10.3389\/fimmu.2019.00168"},{"key":"2400_CR168","doi-asserted-by":"crossref","unstructured":"Toor SM, Murshed K, Al-Dhaheri M, Khawar M, Abu Nada M, Elkord E. Immune Checkpoints in Circulating and Tumor-Infiltrating CD4+ T Cell Subsets in Colorectal Cancer Patients. Front Immunol . 2019;10:2936. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31921188.","DOI":"10.3389\/fimmu.2019.02936"},{"key":"2400_CR169","doi-asserted-by":"crossref","unstructured":"Shayan G, Srivastava R, Li J, Schmitt N, Kane LP, Ferris RL. Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer. Oncoimmunology . 2017;6:e1261779. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28197389.","DOI":"10.1080\/2162402X.2016.1261779"},{"key":"2400_CR170","doi-asserted-by":"crossref","unstructured":"Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med . 2018;24:541\u201350. Available from: https:\/\/www.nature.com\/articles\/s41591-018-0014-x.","DOI":"10.1038\/s41591-018-0014-x"},{"key":"2400_CR171","doi-asserted-by":"crossref","unstructured":"Teng MWL, Ngiow SF, Ribas A, Smyth MJ. Classifying Cancers Based on T-cell Infiltration and PD-L1. Cancer Res . 2015;75:2139\u201345. Available from: https:\/\/aacrjournals.org\/cancerres\/article\/75\/11\/2139\/603481\/Classifying-Cancers-Based-on-T-cell-Infiltration.","DOI":"10.1158\/0008-5472.CAN-15-0255"},{"key":"2400_CR172","doi-asserted-by":"crossref","unstructured":"Wang Y, Meraz IM, Qudratullah M, Kotagiri S, Han Y, Xi Y, et al. Mutation of SMARCA4 Induces Cancer Cell-Intrinsic Defects in the Enhancer Landscape and Resistance to Immunotherapy. Cancer Res . 2025; Available from: https:\/\/aacrjournals.org\/cancerres\/article\/doi\/10.1158\/0008-5472.CAN-24-2054\/754180\/Mutation-of-SMARCA4-Induces-Cancer-Cell-Intrinsic.","DOI":"10.1158\/0008-5472.c.7851710"},{"key":"2400_CR173","doi-asserted-by":"crossref","unstructured":"Topper MJ, Vaz M, Marrone KA, Brahmer JR, Baylin SB. The emerging role of epigenetic therapeutics in immuno-oncology. Nat Rev Clin Oncol . 2020;17:75\u201390. Available from: https:\/\/www.nature.com\/articles\/s41571-019-0266-5.","DOI":"10.1038\/s41571-019-0266-5"},{"key":"2400_CR174","doi-asserted-by":"crossref","unstructured":"Liang Y, Turcan S. Epigenetic Drugs and Their Immune Modulating Potential in Cancers. Biomedicines . 2022;10:211. Available from: https:\/\/www.mdpi.com\/2227-9059\/10\/2\/211.","DOI":"10.3390\/biomedicines10020211"},{"key":"2400_CR175","doi-asserted-by":"crossref","unstructured":"Licht JD, Bennett RL. Leveraging epigenetics to enhance the efficacy of immunotherapy. Clin Epigenetics . 2021;13:115. Available from: https:\/\/clinicalepigeneticsjournal.biomedcentral.com\/articles\/10.1186\/s13148-021-01100-x.","DOI":"10.1186\/s13148-021-01100-x"},{"key":"2400_CR176","doi-asserted-by":"crossref","unstructured":"Kakaradov B, Arsenio J, Widjaja CE, He Z, Aigner S, Metz PJ, et al. Early transcriptional and epigenetic regulation of CD8+ T cell differentiation revealed by single-cell RNA sequencing. Nat Immunol . 2017;18:422\u201332. Available from: https:\/\/www.nature.com\/articles\/ni.3688.","DOI":"10.1038\/ni.3688"},{"key":"2400_CR177","doi-asserted-by":"publisher","first-page":"8240","DOI":"10.18632\/oncotarget.6973","volume":"7","author":"HH Chua","year":"2016","unstructured":"Chua HH, Huang CS, Weng PL, Yeh TH. TSG\u0394154-1054 splice variant increases TSG101 oncogenicity by inhibiting its E3-ligase-mediated proteasomal degradation. Oncotarget. 2016;7:8240\u201352.","journal-title":"Oncotarget"},{"key":"2400_CR178","doi-asserted-by":"crossref","unstructured":"Kim H-J, Cantor H, Cosmopoulos K. Overcoming Immune Checkpoint Blockade Resistance via EZH2 Inhibition. Trends Immunol . 2020;41:948\u201363. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471490620301873.","DOI":"10.1016\/j.it.2020.08.010"},{"key":"2400_CR179","doi-asserted-by":"crossref","unstructured":"Peng D, Kryczek I, Nagarsheth N, Zhao L, Wei S, Wang W, et al. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature . 2015;527:249\u201353. Available from: https:\/\/www.nature.com\/articles\/nature15520.","DOI":"10.1038\/nature15520"},{"key":"2400_CR180","doi-asserted-by":"crossref","unstructured":"Olino K, Park T, Ahuja N. Exposing Hidden Targets: Combining epigenetic and immunotherapy to overcome cancer resistance. Semin Cancer Biol . 2020;65:114\u201322. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044579X2030002X.","DOI":"10.1016\/j.semcancer.2020.01.001"},{"key":"2400_CR181","doi-asserted-by":"crossref","unstructured":"Porazzi P, Nason S, Yang Z, Carturan A, Ghilardi G, Guruprasad P, et al. EZH1\/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer models. Cancer Cell . 2025;43:537\u2013551.e7. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1535610825000315.","DOI":"10.1016\/j.ccell.2025.01.013"},{"key":"2400_CR182","doi-asserted-by":"crossref","unstructured":"Rosenthal R, Cadieux EL, Salgado R, Bakir M Al, Moore DA, Hiley CT, et al. Neoantigen-directed immune escape in lung cancer evolution. Nature . 2019;567:479\u201385. Available from: https:\/\/www.nature.com\/articles\/s41586-019-1032-7.","DOI":"10.1038\/s41586-019-1032-7"},{"key":"2400_CR183","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","volume":"19","author":"A Garcia-Diaz","year":"2017","unstructured":"Garcia-Diaz A, Shin DS, Moreno BH, Saco J, Escuin-Ordinas H, Rodriguez GA, et al. Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression. Cell Rep. 2017;19:1189\u2013201.","journal-title":"Cell Rep"},{"key":"2400_CR184","doi-asserted-by":"crossref","unstructured":"Leone RD, Powell JD. Metabolism of immune cells in cancer. Nat Rev Cancer. 2020;20:516. Available from: https:\/\/www.pmc\/articles\/PMC8041116\/.","DOI":"10.1038\/s41568-020-0273-y"},{"key":"2400_CR185","doi-asserted-by":"crossref","unstructured":"Faubert B, Solmonson A, DeBerardinis RJ. Metabolic reprogramming and cancer progression. Science. 2020;368. Available from: https:\/\/www.science.org\/doi\/10.1126\/science.aaw5473.","DOI":"10.1126\/science.aaw5473"},{"key":"2400_CR186","doi-asserted-by":"crossref","unstructured":"Crump LS, Floyd JL, Kuo L-W, Post MD, Bickerdike M, O\u2019Neill K, et al. Targeting Tryptophan Catabolism in Ovarian Cancer to Attenuate Macrophage Infiltration and PD-L1 Expression. Cancer Res Commun . 2024;4:822\u201333. Available from: https:\/\/aacrjournals.org\/cancerrescommun\/article\/4\/3\/822\/735165\/Targeting-Tryptophan-Catabolism-in-Ovarian-Cancer.","DOI":"10.1158\/2767-9764.CRC-23-0513"},{"key":"2400_CR187","doi-asserted-by":"crossref","unstructured":"Liberti MV, Locasale JW. The warburg effect: how does it benefit cancer cells? Trends Biochem Sci. 2016;41:211\u20138. Available from: http:\/\/www.cell.com\/article\/S0968000415002418\/fulltext.","DOI":"10.1016\/j.tibs.2015.12.001"},{"key":"2400_CR188","doi-asserted-by":"crossref","unstructured":"Hanahan D. Hallmarks of cancer: new dimensions. 2022;12:31\u201346. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/35022204\/.","DOI":"10.1158\/2159-8290.CD-21-1059"},{"key":"2400_CR189","doi-asserted-by":"crossref","unstructured":"Aksoylar H-I, Tijaro-Ovalle NM, Boussiotis VA, Patsoukis N. T cell metabolism in cancer immunotherapy. Immunometabolism. 2020;2. Available from: https:\/\/www.pmc\/articles\/PMC7341973\/.","DOI":"10.20900\/immunometab20200020"},{"key":"2400_CR190","doi-asserted-by":"crossref","unstructured":"Beckermann KE, Dudzinski SO, Rathmell JC. Dysfunctional T cell metabolism in the tumor microenvironment. Cytokine Growth Factor Rev. 2017;35:7\u201314. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/28456467\/.","DOI":"10.1016\/j.cytogfr.2017.04.003"},{"key":"2400_CR191","doi-asserted-by":"crossref","unstructured":"Li X, Wenes M, Romero P, Huang SCC, Fendt SM, Ho PC. Navigating metabolic pathways to enhance antitumour immunity and immunotherapy. Nat Rev Clin Oncol; 2019:425\u201341. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/30914826\/.","DOI":"10.1038\/s41571-019-0203-7"},{"key":"2400_CR192","doi-asserted-by":"crossref","unstructured":"Zheng S, Li H, Li Y, Chen X, Shen J, Chen M, et al. The emerging role of glycolysis and immune evasion in gastric cancer. Cancer Cell Int . 2023;23:317. Available from: https:\/\/cancerci.biomedcentral.com\/articles\/10.1186\/s12935-023-03169-1.","DOI":"10.1186\/s12935-023-03169-1"},{"key":"2400_CR193","doi-asserted-by":"crossref","unstructured":"Takahashi H, Kawabata-Iwakawa R, Ida S, Mito I, Tada H, Chikamatsu K. Upregulated glycolysis correlates with tumor progression and immune evasion in head and neck squamous cell carcinoma. Sci Rep. 2021;11. Available from: https:\/\/www.pmc\/articles\/PMC8423753\/.","DOI":"10.1038\/s41598-021-97292-6"},{"key":"2400_CR194","doi-asserted-by":"crossref","unstructured":"Warburg O. On the Origin of Cancer Cells. Science (80- ) . 1956;123:309\u201314. Available from: https:\/\/www.science.org\/doi\/10.1126\/science.123.3191.309.","DOI":"10.1126\/science.123.3191.309"},{"key":"2400_CR195","doi-asserted-by":"crossref","unstructured":"Ottensmeier CH, Perry KL, Harden EL, Stasakova J, Jenei V, Fleming J, et al. Upregulated glucose metabolism correlates inversely with CD8+ T-cell infiltration and survival in squamous cell carcinoma. Cancer Res. 2016;76:4136\u201348. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/27206847\/.","DOI":"10.1158\/0008-5472.CAN-15-3121"},{"key":"2400_CR196","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.bbabio.2010.09.003","volume":"1807","author":"G Solaini","year":"2011","unstructured":"Solaini G, Sgarbi G, Baracca A. Oxidative phosphorylation in cancer cells. Biochim Biophys Acta-Bioenerg. 2011;1807:534\u201342.","journal-title":"Biochim Biophys Acta-Bioenerg"},{"key":"2400_CR197","doi-asserted-by":"crossref","unstructured":"Singer K, Kastenberger M, Gottfried E, Hammerschmied CG, B\u00fcttner M, Aigner M, et al. Warburg phenotype in renal cell carcinoma: High expression of glucose\u2010transporter 1 (GLUT\u20101) correlates with low CD8 + T\u2010cell infiltration in the tumor. Int J Cancer . 2011;128:2085\u201395. Available from:https:\/\/www.science.org\/doi\/10.1002\/ijc.25543.","DOI":"10.1002\/ijc.25543"},{"key":"2400_CR198","doi-asserted-by":"crossref","unstructured":"Brand A, Singer K, Koehl GE, Kolitzus M, Schoenhammer G, Thiel A, et al. LDHA-Associated lactic acid production blunts tumor immunosurveillance by T and NK Cells. Cell Metab. 2016;24:657\u201371. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/27641098\/.","DOI":"10.1016\/j.cmet.2016.08.011"},{"key":"2400_CR199","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2018.11.004","author":"R Ramapriyan","year":"2019","unstructured":"Ramapriyan R, Caetano MS, Barsoumian HB, Mafra ACP, Zambalde EP, Menon H, et al. Altered cancer metabolism in mechanisms of immunotherapy resistance. Pharmacol Ther. 2019. https:\/\/doi.org\/10.1016\/j.pharmthera.2018.11.004.","journal-title":"Pharmacol Ther"},{"key":"2400_CR200","doi-asserted-by":"crossref","unstructured":"Fu Z, Chen S, Zhu Y, Zhang D, Xie P, Jiao Q, et al. Proteolytic regulation of CD73 by TRIM21 orchestrates tumor immunogenicity. Sci Adv. 2023;9. Available from: https:\/\/www.science.org\/doi\/10.1126\/sciadv.add6626.","DOI":"10.1126\/sciadv.add6626"},{"key":"2400_CR201","unstructured":"Wang J, Yang Y, Shao F, Meng Y, Guo D, He J, et al. Acetate reprogrammes tumour metabolism and promotes PD-L1 expression and immune evasion by upregulating c-Myc. Nat Metab. 2024;1\u201318. Available from: https:\/\/www.nature.com\/articles\/s42255-024-01037-4."},{"key":"2400_CR202","doi-asserted-by":"crossref","unstructured":"Hartmann FJ, Mrdjen D, McCaffrey E, Glass DR, Greenwald NF, Bharadwaj A, et al. Single-cell metabolic profiling of human cytotoxic T cells. Nat Biotechnol. 2021;39:186\u201397. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/32868913\/.","DOI":"10.1038\/s41587-020-0651-8"},{"key":"2400_CR203","doi-asserted-by":"crossref","unstructured":"Crane CA, Austgen K, Haberthur K, Hofmann C, Moyes KW, Avanesyan L, et al. Immune evasion mediated by tumor-derived lactate dehydrogenase induction of NKG2D ligands on myeloid cells in glioblastoma patients. Proc Natl Acad Sci . 2014;111:12823\u20138. Available from: https:\/\/pnas.org\/doi\/full\/10.1073\/pnas.1413933111.","DOI":"10.1073\/pnas.1413933111"},{"key":"2400_CR204","doi-asserted-by":"crossref","unstructured":"Chang CH, Qiu J, O\u2019Sullivan D, Buck MD, Noguchi T, Curtis JD, et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell. 2015;162:1229\u201341. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/26321679\/.","DOI":"10.1016\/j.cell.2015.08.016"},{"key":"2400_CR205","doi-asserted-by":"crossref","unstructured":"Chuang YM, Tzeng SF, Ho PC, Tsai CH. Immunosurveillance encounters cancer metabolism. EMBO Rep. 2024;25:471\u201388. Available from: https:\/\/www.embopress.org\/doi\/10.1038\/s44319-023-00038-w.","DOI":"10.1038\/s44319-023-00038-w"},{"key":"2400_CR206","doi-asserted-by":"crossref","unstructured":"Cadenas-De Miguel S, Lucianer G, Elia I. The metabolic cross-talk between cancer and T cells. Trends Biochem Sci. 2023;48:597\u2013609. Available from: http:\/\/www.cell.com\/article\/S0968000423000804\/fulltext.","DOI":"10.1016\/j.tibs.2023.03.004"},{"key":"2400_CR207","doi-asserted-by":"crossref","unstructured":"P\u00e5lsson-McDermott EM, O\u2019Neill LAJ. Gang of 3: How the Krebs cycle-linked metabolites itaconate, succinate, and fumarate regulate macrophages and inflammation. Cell Metab . 2025; Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S155041312500107X.","DOI":"10.1016\/j.cmet.2025.03.004"},{"key":"2400_CR208","doi-asserted-by":"crossref","unstructured":"Schofield JH, Longo J, Sheldon RD, Albano E, Ellis AE, Hawk MA, et al. Acod1 expression in cancer cells promotes immune evasion through the generation of inhibitory peptides. Cell Rep . 2024;43:113984. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211124724003127.","DOI":"10.1016\/j.celrep.2024.113984"},{"key":"2400_CR209","doi-asserted-by":"crossref","unstructured":"Fan Y, Dan W, Wang Y, Ma Z, Jian Y, Liu T, et al. Itaconate transporter SLC13A3 confers immunotherapy resistance via alkylation-mediated stabilization of PD-L1. Cell Metab . 2025;37:514\u2013526.e5. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1550413124004807.","DOI":"10.1016\/j.cmet.2024.11.012"},{"issue":"4","key":"2400_CR210","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1038\/s44321-024-00051-z","volume":"16","author":"Y Yang","year":"2024","unstructured":"Yang Y, Li Z, Wang Y, Gao J, Meng Y, Wang S, et al. The regulatory relationship between NAMPT and PD-L1 in cancer and identification of a dual-targeting inhibitor. EMBO Mol Med. 2024;16(4):885\u2013903.","journal-title":"EMBO Mol Med"},{"key":"2400_CR211","unstructured":"Chang H-C, Tsai C-Y, Hsu C-L, Tai T-S, Cheng M-L, Chuang Y-M, et al. Asparagine deprivation enhances T cell antitumour response in patients via ROS-mediated metabolic and signal adaptations. Nat Metab . 2025; Available from: https:\/\/www.nature.com\/articles\/s42255-025-01245-6."},{"key":"2400_CR212","doi-asserted-by":"crossref","unstructured":"Salemme V, Centonze G, Cavallo F, Defilippi P, Conti L. The Crosstalk Between Tumor Cells and the Immune Microenvironment in Breast Cancer: Implications for Immunotherapy. Front Oncol . 2021;11. Available from: https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.610303\/full.","DOI":"10.3389\/fonc.2021.610303"},{"key":"2400_CR213","doi-asserted-by":"crossref","unstructured":"Mao X, Xu J, Wang W, Liang C, Hua J, Liu J, et al. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Mol Cancer . 2021;20:131. Available from: https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-021-01428-1.","DOI":"10.1186\/s12943-021-01428-1"},{"key":"2400_CR214","doi-asserted-by":"crossref","unstructured":"Fang J, Lu Y, Zheng J, Jiang X, Shen H, Shang X, et al. Exploring the crosstalk between endothelial cells, immune cells, and immune checkpoints in the tumor microenvironment: new insights and therapeutic implications. Cell Death Dis. 2023;14:1\u201315. Available from: https:\/\/www.nature.com\/articles\/s41419-023-06119-x.","DOI":"10.1038\/s41419-023-06119-x"},{"key":"2400_CR215","doi-asserted-by":"crossref","unstructured":"Kay EJ, Zanivan S. The tumor microenvironment is an ecosystem sustained by metabolic interactions. Cell Rep . 2025;44:115432. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211124725002037.","DOI":"10.1016\/j.celrep.2025.115432"},{"key":"2400_CR216","doi-asserted-by":"crossref","unstructured":"Yang M-Q, Zhang S-L, Sun L, Huang L-T, Yu J, Zhang J-H, et al. Targeting mitochondria: restoring the antitumor efficacy of exhausted T cells. Mol Cancer . 2024;23:260. Available from: https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-024-02175-9.","DOI":"10.1186\/s12943-024-02175-9"},{"key":"2400_CR217","doi-asserted-by":"crossref","unstructured":"Liu M, Fu X, Yi Q, Xu E, Dong L. Impaired mitochondrial oxidative phosphorylation induces CD8+ T cell exhaustion. Biochem Biophys Res Commun . 2024;734:150738. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X24012749.","DOI":"10.1016\/j.bbrc.2024.150738"},{"key":"2400_CR218","doi-asserted-by":"crossref","unstructured":"Desd\u00edn-Mic\u00f3 G, Soto-Heredero G, Mittelbrunn M. Mitochondrial activity in T cells. Mitochondrion . 2018;41:51\u20137. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567724917301927.","DOI":"10.1016\/j.mito.2017.10.006"},{"key":"2400_CR219","doi-asserted-by":"crossref","unstructured":"Zhang L, Zhang W, Li Z, Lin S, Zheng T, Hao B, et al. Mitochondria dysfunction in CD8+ T cells as an important contributing factor for cancer development and a potential target for cancer treatment: a review. J Exp Clin Cancer Res . 2022;41:227. Available from: https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-022-02439-6.","DOI":"10.1186\/s13046-022-02439-6"},{"key":"2400_CR220","doi-asserted-by":"crossref","unstructured":"Yang M-Q, Zhang S-L, Sun L, Huang L-T, Yu J, Zhang J-H, et al. Targeting mitochondria: restoring the antitumor efficacy of exhausted T cells. Mol Cancer . 2024;23:260. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/39563438.","DOI":"10.1186\/s12943-024-02175-9"},{"key":"2400_CR221","doi-asserted-by":"crossref","unstructured":"Mortazavi Farsani SS, Soni J, Jin L, Yadav AK, Bansal S, Mi T, et al. Pyruvate kinase M2 activation reprograms mitochondria in CD8 T cells, enhancing effector functions and efficacy of anti-PD1 therapy. Cell Metab . 2025;37:1294\u20131310.e7. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1550413125001068.","DOI":"10.1016\/j.cmet.2025.03.003"},{"key":"2400_CR222","doi-asserted-by":"crossref","unstructured":"Vardhana SA, Hwee MA, Berisa M, Wells DK, Yost KE, King B, et al. Impaired mitochondrial oxidative phosphorylation limits the self-renewal of T cells exposed to persistent antigen. Nat Immunol . 2020;21:1022\u201333. Available from: https:\/\/www.nature.com\/articles\/s41590-020-0725-2.","DOI":"10.1038\/s41590-020-0725-2"},{"key":"2400_CR223","doi-asserted-by":"crossref","unstructured":"Yu Y-R, Imrichova H, Wang H, Chao T, Xiao Z, Gao M, et al. Disturbed mitochondrial dynamics in CD8+ TILs reinforce T cell exhaustion. Nat Immunol . 2020;21:1540\u201351. Available from: https:\/\/www.nature.com\/articles\/s41590-020-0793-3.","DOI":"10.1038\/s41590-020-0793-3"},{"key":"2400_CR224","doi-asserted-by":"crossref","unstructured":"Scharping NE, Menk A V., Moreci RS, Whetstone RD, Dadey RE, Watkins SC, et al. The Tumor Microenvironment Represses T Cell Mitochondrial Biogenesis to Drive Intratumoral T Cell Metabolic Insufficiency and Dysfunction. Immunity . 2016;45:374\u201388. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1074761316302825.","DOI":"10.1016\/j.immuni.2016.07.009"},{"key":"2400_CR225","doi-asserted-by":"crossref","unstructured":"Scharping NE, Rivadeneira DB, Menk A V., Vignali PDA, Ford BR, Rittenhouse NL, et al. Mitochondrial stress induced by continuous stimulation under hypoxia rapidly drives T cell exhaustion. Nat Immunol . 2021;22:205\u201315. Available from: https:\/\/www.nature.com\/articles\/s41590-020-00834-9.","DOI":"10.1038\/s41590-020-00834-9"},{"key":"2400_CR226","doi-asserted-by":"crossref","unstructured":"Gamal W, Goedhart NB, Simon-Molas H, Mediavilla-Varela M, Uriepero-Palma A, Peters FS, et al. Mitigating T-cell mitochondrial dysfunction in CLL to augment CAR T-cell therapy: evaluation in an immunocompetent model. Blood Adv . 2025;9:2511\u201329. Available from: https:\/\/ashpublications.org\/bloodadvances\/article\/9\/10\/2511\/535574\/Mitigating-T-cell-mitochondrial-dysfunction-in-CLL.","DOI":"10.1182\/bloodadvances.2024014822"},{"key":"2400_CR227","doi-asserted-by":"crossref","unstructured":"Chamoto K, Chowdhury PS, Kumar A, Sonomura K, Matsuda F, Fagarasan S, et al. Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity. Proc Natl Acad Sci . 2017;114. Available from: https:\/\/pnas.org\/doi\/full\/10.1073\/pnas.1620433114.","DOI":"10.1073\/pnas.1620433114"},{"key":"2400_CR228","doi-asserted-by":"crossref","unstructured":"Menk A V., Scharping NE, Rivadeneira DB, Calderon MJ, Watson MJ, Dunstane D, et al. 4\u20131BB costimulation induces T cell mitochondrial function and biogenesis enabling cancer immunotherapeutic responses. J Exp Med . 2018;215:1091\u2013100. Available from: https:\/\/rupress.org\/jem\/article\/215\/4\/1091\/42406\/4-1BB-costimulation-induces-T-cell-mitochondrial.","DOI":"10.1084\/jem.20171068"},{"key":"2400_CR229","unstructured":"Monson KR, Ferguson R, Handzlik JE, Morales L, Xiong J, Chat V, et al. Inherited mitochondrial genetics as a predictor of immune checkpoint inhibition efficacy in melanoma. Nat Med . 2025; Available from: https:\/\/www.nature.com\/articles\/s41591-025-03699-3."},{"key":"2400_CR230","doi-asserted-by":"crossref","unstructured":"Saha T, Dash C, Jayabalan R, Khiste S, Kulkarni A, Kurmi K, et al. Intercellular nanotubes mediate mitochondrial trafficking between cancer and immune cells. Nat Nanotechnol . 2022;17:98\u2013106. Available from: https:\/\/www.nature.com\/articles\/s41565-021-01000-4.","DOI":"10.1038\/s41565-021-01000-4"},{"key":"2400_CR231","doi-asserted-by":"crossref","unstructured":"Ikeda H, Kawase K, Nishi T, Watanabe T, Takenaga K, Inozume T, et al. Immune evasion through mitochondrial transfer in the tumour microenvironment. Nature . 2025;638:225\u201336. Available from: https:\/\/www.nature.com\/articles\/s41586-024-08439-0.","DOI":"10.1038\/s41586-024-08439-0"},{"key":"2400_CR232","doi-asserted-by":"crossref","unstructured":"Baldwin JG, Heuser-Loy C, Saha T, Schelker RC, Slavkovic-Lukic D, Strieder N, et al. Intercellular nanotube-mediated mitochondrial transfer enhances T cell metabolic fitness and antitumor efficacy. Cell . 2024;187:6614\u20136630.e21. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0092867424009565.","DOI":"10.1016\/j.cell.2024.08.029"},{"key":"2400_CR233","doi-asserted-by":"crossref","unstructured":"Brestoff JR, Singh KK, Aquilano K, Becker LB, Berridge M V., Boilard E, et al. Recommendations for mitochondria transfer and transplantation nomenclature and characterization. Nat Metab . 2025;7:53\u201367. Available from: https:\/\/www.nature.com\/articles\/s42255-024-01200-x.","DOI":"10.1038\/s42255-024-01200-x"},{"key":"2400_CR234","doi-asserted-by":"crossref","unstructured":"Maggiorani D, Le O, Lisi V, Landais S, Moquin-Beaudry G, Lavall\u00e9e VP, et al. Senescence drives immunotherapy resistance by inducing an immunosuppressive tumor microenvironment. Nat Commun. 2024;15:1\u201315. Available from: https:\/\/www.nature.com\/articles\/s41467-024-46769-9.","DOI":"10.1038\/s41467-024-46769-9"},{"key":"2400_CR235","doi-asserted-by":"crossref","unstructured":"Ma F, Liu X, Zhang Y, Tao Y, Zhao L, Abusalamah H, et al. Tumor extracellular vesicle\u2013derived PD-L1 promotes T cell senescence through lipid metabolism reprogramming. Sci Transl Med . 2025;17. Available from: https:\/\/www.science.org\/doi\/10.1126\/scitranslmed.adm7269.","DOI":"10.1126\/scitranslmed.adm7269"},{"key":"2400_CR236","doi-asserted-by":"crossref","unstructured":"Hwang HJ, Kang D, Shin J, Jung J, Ko S, Jung KH, et al. Therapy-induced senescent cancer cells contribute to cancer progression by promoting ribophorin 1-dependent PD-L1 upregulation. Nat Commun . 2025;16:353. Available from: https:\/\/www.nature.com\/articles\/s41467-024-54132-1.","DOI":"10.1038\/s41467-024-54132-1"},{"key":"2400_CR237","doi-asserted-by":"crossref","unstructured":"Wang T-W, Johmura Y, Suzuki N, Omori S, Migita T, Yamaguchi K, et al. Blocking PD-L1\u2013PD-1 improves senescence surveillance and ageing phenotypes. Nature . 2022;611:358\u201364. Available from: https:\/\/www.nature.com\/articles\/s41586-022-05388-4.","DOI":"10.1038\/s41586-022-05388-4"},{"key":"2400_CR238","doi-asserted-by":"crossref","unstructured":"Tan Z, Li H, Huang Y, Fu S, Wang H, Wang J. Multi-omics landscape analysis reveals the pan-cancer association of arginine biosynthesis genes with tumor immune evasion and therapy resistance. Heliyon . 2024;10:e26804. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024028354.","DOI":"10.1016\/j.heliyon.2024.e26804"},{"key":"2400_CR239","doi-asserted-by":"crossref","unstructured":"Zhu Y, Zhou Z, Du X, Lin X, Liang Z-M, Chen S, et al. Cancer cell-derived arginine fuels polyamine biosynthesis in tumor-associated macrophages to promote immune evasion. Cancer Cell . 2025; Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1535610825001163.","DOI":"10.1016\/j.ccell.2025.03.015"},{"key":"2400_CR240","doi-asserted-by":"crossref","unstructured":"Page R, Martinez O, Larcombe-Young D, Bugallo-Blanco E, Papa S, Perucha E. GLUT5 armouring enhances adoptive T cell therapy anti-tumour activity under glucose-limiting conditions. Immunother Adv . 2025; Available from: https:\/\/academic.oup.com\/immunotherapyadv\/advance-article\/doi\/10.1093\/immadv\/ltaf018\/8123265.","DOI":"10.1101\/2025.01.16.633365"},{"key":"2400_CR241","doi-asserted-by":"crossref","unstructured":"Schild T, Wallisch P, Zhao Y, Wang Y-T, Haughton L, Chirayil R, et al. Metabolic engineering to facilitate anti-tumor immunity. Cancer Cell . 2025;43:552\u2013562.e9. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S153561082500056X.","DOI":"10.1016\/j.ccell.2025.02.004"},{"key":"2400_CR242","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2022.975986","volume":"13","author":"P Fang","year":"2022","unstructured":"Fang P, Zhou J, Liang Z, Yang Y, Luan S, Xiao X, et al. Immunotherapy resistance in esophageal cancer: Possible mechanisms and clinical implications. Front Immunol. 2022;13:1\u201317.","journal-title":"Front Immunol"},{"key":"2400_CR243","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1158\/2326-6066.CIR-16-0329","volume":"5","author":"J Zhou","year":"2017","unstructured":"Zhou J, Mahoney KM, Giobbie-Hurder A, Zhao F, Lee S, Liao X, et al. Soluble PD-L1 as a biomarker in malignant melanoma treated with checkpoint blockade. Cancer Immunol Res. 2017;5:480\u201392.","journal-title":"Cancer Immunol Res"},{"key":"2400_CR244","doi-asserted-by":"publisher","first-page":"105741","DOI":"10.1016\/j.phrs.2021.105741","volume":"170","author":"H Ying","year":"2021","unstructured":"Ying H, Zhang X, Duan Y, Lao M, Xu J, Yang H, et al. Non-cytomembrane PD-L1: An atypical target for cancer. Pharmacol Res. 2021;170:105741.","journal-title":"Pharmacol Res"},{"key":"2400_CR245","doi-asserted-by":"crossref","unstructured":"Jia Y, Li X, Zhao C, Ren S, Su C, Gao G, et al. Soluble PD-L1 as a Predictor of the Response to EGFR-TKIs in Non-small Cell Lung Cancer Patients With EGFR Mutations. Front Oncol . 2020;10. Available from: https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.01455\/full.","DOI":"10.3389\/fonc.2020.01455"},{"key":"2400_CR246","doi-asserted-by":"crossref","unstructured":"Finkelmeier F, Canli \u00d6, Tal A, Pleli T, Trojan J, Schmidt M, et al. High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis. Eur J Cancer . 2016;59:152\u20139. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095980491600157X.","DOI":"10.1016\/j.ejca.2016.03.002"},{"key":"2400_CR247","doi-asserted-by":"crossref","unstructured":"Orme JJ, Jazieh KA, Xie T, Harrington S, Liu X, Ball M, et al. ADAM10 and ADAM17 cleave PD-L1 to mediate PD-(L)1 inhibitor resistance. Oncoimmunology. 2020;9. Available from: https:\/\/www.tandfonline.com\/doi\/abs\/10.1080\/2162402X.2020.1744980.","DOI":"10.1080\/2162402X.2020.1744980"},{"key":"2400_CR248","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s00262-018-2282-1","volume":"68","author":"KM Mahoney","year":"2019","unstructured":"Mahoney KM, Shukla SA, Patsoukis N, Chaudhri A, Browne EP, Arazi A, et al. A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression. Cancer Immunol Immunother. 2019;68:421\u201332.","journal-title":"Cancer Immunol Immunother"},{"key":"2400_CR249","doi-asserted-by":"crossref","unstructured":"Liu J, Peng X, Yang S, Li X, Huang M, Wei S, et al. Extracellular vesicle PD-L1 in reshaping tumor immune microenvironment: biological function and potential therapy strategies. Cell Commun Signal. 2022;20:1\u201318. Available from: https:\/\/biosignaling.biomedcentral.com\/articles\/10.1186\/s12964-021-00816-w.","DOI":"10.1186\/s12964-021-00816-w"},{"key":"2400_CR250","doi-asserted-by":"crossref","unstructured":"Zhu X, Lang J. Soluble PD-1 and PD-L1: Predictive and prognostic significance in cancer. Oncotarget. Impact Journals; 2017:97671\u201382. Available from: https:\/\/www.oncotarget.com\/article\/18311\/text\/.","DOI":"10.18632\/oncotarget.18311"},{"key":"2400_CR251","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1084\/jem.20180870","volume":"216","author":"B Gong","year":"2019","unstructured":"Gong B, Kiyotani K, Sakata S, Nagano S, Kumehara S, Baba S, et al. Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer. J Exp Med. 2019;216:982\u20131000. https:\/\/doi.org\/10.1084\/jem.20180870.","journal-title":"J Exp Med"},{"key":"2400_CR252","doi-asserted-by":"crossref","unstructured":"Sagawa R, Sakata S, Gong B, Seto Y, Takemoto A, Takagi S, et al. Soluble PD-L1 works as a decoy in lung cancer immunotherapy via alternative polyadenylation. JCI insight. 2022;7. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/34874919\/.","DOI":"10.1172\/jci.insight.153323"},{"key":"2400_CR253","doi-asserted-by":"crossref","unstructured":"Poggio M, Hu T, Pai CC, Chu B, Belair CD, Chang A, et al. Suppression of exosomal PD-L1 induces systemic anti-tumor immunity and memory. Cell. 2019;177:414. Available from: https:\/\/www.pmc\/articles\/PMC6499401\/.","DOI":"10.1016\/j.cell.2019.02.016"},{"key":"2400_CR254","doi-asserted-by":"crossref","unstructured":"Hayashi H, Chamoto K, Hatae R, Kurosaki T, Togashi Y, Fukuoka K, et al. Soluble immune checkpoint factors reflect exhaustion of antitumor immunity and response to PD-1 blockade. J Clin Invest . 2024;134. Available from: https:\/\/www.jci.org\/articles\/view\/168318.","DOI":"10.1172\/JCI168318"},{"key":"2400_CR255","doi-asserted-by":"crossref","unstructured":"Han B, Dong L, Zhou J, Yang Y, Guo J, Xuan Q, et al. The clinical implication of soluble PD-L1 (sPD-L1) in patients with breast cancer and its biological function in regulating the function of T lymphocyte. Cancer Immunol Immunother. 2021;70:2893\u2013909. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/33688997\/.","DOI":"10.1007\/s00262-021-02898-4"},{"key":"2400_CR256","doi-asserted-by":"publisher","first-page":"e50256","DOI":"10.7554\/eLife.50256","volume":"8","author":"KW Ng","year":"2019","unstructured":"Ng KW, Attig J, Young GR, Ottina E, Papamichos SI, Kotsianidis I, et al. Soluble PD-L1 generated by endogenous retroelement exaptation is a receptor antagonist. Elife. 2019;8:e50256.","journal-title":"Elife"},{"key":"2400_CR257","doi-asserted-by":"crossref","unstructured":"Cheng Y, Wang C, Wang Y, Dai L. Soluble PD-L1 as a predictive biomarker in lung cancer: a systematic review and meta-analysis. Future Oncol. 2022:261\u201373. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/34874185\/.","DOI":"10.2217\/fon-2021-0641"},{"key":"2400_CR258","doi-asserted-by":"crossref","unstructured":"Kawakami H, Sunakawa Y, Inoue E, Matoba R, Noda K, Sato T, et al. Soluble PD-L1 predicts prognosis for gastric cancer patients treated with nivolumab: blood-based biomarker analysis for the DELIVER trial. Eur J Cancer. 2023. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804923000643.","DOI":"10.1016\/j.ejca.2023.02.003"},{"issue":"1","key":"2400_CR259","doi-asserted-by":"publisher","first-page":"1846901","DOI":"10.1080\/2162402X.2020.1846901","volume":"9","author":"C Montemagno","year":"2020","unstructured":"Montemagno C, Hagege A, Borchiellini D, Thamphya B, Rastoin O, Ambrosetti D, et al. Soluble forms of PD-L1 and PD-1 as prognostic and predictive markers of sunitinib efficacy in patients with metastatic clear cell renal cell carcinoma. Oncoimmunology. 2020;9(1):1846901.","journal-title":"Oncoimmunology."},{"key":"2400_CR260","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ejca.2016.03.002","volume":"59","author":"F Finkelmeier","year":"2016","unstructured":"Finkelmeier F, Canli \u00d6, Tal A, Pleli T, Trojan J, Schmidt M, et al. High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis. Eur J Cancer. 2016;59:152\u20139.","journal-title":"Eur J Cancer"},{"key":"2400_CR261","doi-asserted-by":"crossref","unstructured":"Asanuma K, Nakamura T, Hayashi A, Okamoto T, Iino T, Asanuma Y, et al. Soluble programmed death-ligand 1 rather than PD-L1 on tumor cells effectively predicts metastasis and prognosis in soft tissue sarcomas. Sci Rep . 2020;10:9077. Available from: http:\/\/www.nature.com\/articles\/s41598-020-65895-0.","DOI":"10.1038\/s41598-020-65895-0"},{"key":"2400_CR262","doi-asserted-by":"crossref","unstructured":"Ando K, Hamada K, Watanabe M, Ohkuma R, Shida M, Onou R, et al. Plasma Levels of Soluble PD-L1 Correlate With Tumor Regression in Patients With Lung and Gastric Cancer Treated With Immune Checkpoint Inhibitors. Anticancer Res . 2019;39:5195\u2013201. Available from: http:\/\/ar.iiarjournals.org\/lookup\/doi\/10.21873\/anticanres.13716.","DOI":"10.21873\/anticanres.13716"},{"key":"2400_CR263","doi-asserted-by":"crossref","unstructured":"Liu S, Zhu Y, Zhang C, Meng X, Sun B, Zhang G, et al. The Clinical Significance of Soluble Programmed Cell Death-Ligand 1 (sPD-L1) in Patients With Gliomas. Front Oncol . 2020;10. Available from: https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.00009\/full.","DOI":"10.3389\/fonc.2020.00009"},{"key":"2400_CR264","doi-asserted-by":"crossref","unstructured":"Buderath P, Schwich E, Jensen C, Horn PA, Kimmig R, Kasimir-Bauer S, et al. Soluble Programmed Death Receptor Ligands sPD-L1 and sPD-L2 as Liquid Biopsy Markers for Prognosis and Platinum Response in Epithelial Ovarian Cancer. Front Oncol . 2019;9. Available from: https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.01015\/full.","DOI":"10.3389\/fonc.2019.01015"},{"key":"2400_CR265","doi-asserted-by":"crossref","unstructured":"Hooper L V, Littman DR, Macpherson AJ. Interactions between the microbiota and the immune system. Science . 2012;336:1268\u201373. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22674334.","DOI":"10.1126\/science.1223490"},{"key":"2400_CR266","doi-asserted-by":"crossref","unstructured":"Lathrop SK, Bloom SM, Rao SM, Nutsch K, Lio C-W, Santacruz N, et al. Peripheral education of the immune system by colonic commensal microbiota. Nature . 2011;478:250\u20134. Available from: https:\/\/www.nature.com\/articles\/nature10434.","DOI":"10.1038\/nature10434"},{"key":"2400_CR267","doi-asserted-by":"crossref","unstructured":"Levy M, Thaiss CA, Elinav E. Metabolites: messengers between the microbiota and the immune system. Genes Dev . 2016;30:1589\u201397. Available from: http:\/\/genesdev.cshlp.org\/lookup\/doi\/10.1101\/gad.284091.116.","DOI":"10.1101\/gad.284091.116"},{"key":"2400_CR268","doi-asserted-by":"crossref","unstructured":"Furusawa Y, Obata Y, Fukuda S, Endo TA, Nakato G, Takahashi D, et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature . 2013;504:446\u201350. Available from: https:\/\/www.nature.com\/articles\/nature12721.","DOI":"10.1038\/nature12721"},{"key":"2400_CR269","doi-asserted-by":"crossref","unstructured":"Arpaia N, Campbell C, Fan X, Dikiy S, van der Veeken J, DeRoos P, et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature . 2013;504:451\u20135. Available from: https:\/\/www.nature.com\/articles\/nature12726.","DOI":"10.1038\/nature12726"},{"key":"2400_CR270","doi-asserted-by":"crossref","unstructured":"Smith PM, Howitt MR, Panikov N, Michaud M, Gallini CA, Bohlooly-Y M, et al. The Microbial Metabolites, Short-Chain Fatty Acids, Regulate Colonic T reg Cell Homeostasis. Science (80- ) . 2013;341:569\u201373. Available from: https:\/\/www.science.org\/doi\/10.1126\/science.1241165.","DOI":"10.1126\/science.1241165"},{"key":"2400_CR271","doi-asserted-by":"crossref","unstructured":"Zhou L, Ivanov II, Spolski R, Min R, Shenderov K, Egawa T, et al. IL-6 programs TH-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol . 2007;8:967\u201374. Available from: https:\/\/www.nature.com\/articles\/ni1488.","DOI":"10.1038\/ni1488"},{"key":"2400_CR272","doi-asserted-by":"crossref","unstructured":"Korn T, Bettelli E, Gao W, Awasthi A, J\u00e4ger A, Strom TB, et al. IL-21 initiates an alternative pathway to induce proinflammatory TH17 cells. Nature . 2007;448:484\u20137. Available from: https:\/\/www.nature.com\/articles\/nature05970.","DOI":"10.1038\/nature05970"},{"key":"2400_CR273","doi-asserted-by":"crossref","unstructured":"Nurieva R, Yang XO, Martinez G, Zhang Y, Panopoulos AD, Ma L, et al. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature . 2007;448:480\u20133. Available from: https:\/\/www.nature.com\/articles\/nature05969.","DOI":"10.1038\/nature05969"},{"key":"2400_CR274","doi-asserted-by":"crossref","unstructured":"Zhou L, Lopes JE, Chong MMW, Ivanov II, Min R, Victora GD, et al. TGF-\u03b2-induced Foxp3 inhibits TH17 cell differentiation by antagonizing ROR\u03b3t function. Nature . 2008;453:236\u201340. Available from: https:\/\/www.nature.com\/articles\/nature06878.","DOI":"10.1038\/nature06878"},{"key":"2400_CR275","doi-asserted-by":"crossref","unstructured":"Coombes JL, Siddiqui KRR, Arancibia-C\u00e1rcamo C V., Hall J, Sun C-M, Belkaid Y, et al. A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-\u03b2\u2013 and retinoic acid\u2013dependent mechanism. J Exp Med . 2007;204:1757\u201364. Available from: https:\/\/rupress.org\/jem\/article\/204\/8\/1757\/46978\/A-functionally-specialized-population-of-mucosal.","DOI":"10.1084\/jem.20070590"},{"key":"2400_CR276","doi-asserted-by":"crossref","unstructured":"Kang SG, Lim HW, Andrisani OM, Broxmeyer HE, Kim CH. Vitamin A Metabolites Induce Gut-Homing FoxP3+ Regulatory T Cells. J Immunol . 2007;179:3724\u201333. Available from: https:\/\/journals.aai.org\/jimmunol\/article\/179\/6\/3724\/76360\/Vitamin-A-Metabolites-Induce-Gut-Homing-FoxP3.","DOI":"10.4049\/jimmunol.179.6.3724"},{"key":"2400_CR277","doi-asserted-by":"crossref","unstructured":"Opitz CA, Litzenburger UM, Sahm F, Ott M, Tritschler I, Trump S, et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature . 2011;478:197\u2013203. Available from: https:\/\/www.nature.com\/articles\/nature10491.","DOI":"10.1038\/nature10491"},{"key":"2400_CR278","doi-asserted-by":"crossref","unstructured":"Mezrich JD, Fechner JH, Zhang X, Johnson BP, Burlingham WJ, Bradfield CA. An Interaction between Kynurenine and the Aryl Hydrocarbon Receptor Can Generate Regulatory T Cells. J Immunol . 2010;185:3190\u20138. Available from: https:\/\/academic.oup.com\/jimmunol\/article\/185\/6\/3190\/7977854.","DOI":"10.4049\/jimmunol.0903670"},{"key":"2400_CR279","doi-asserted-by":"crossref","unstructured":"Nguyen NT, Kimura A, Nakahama T, Chinen I, Masuda K, Nohara K, et al. Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism. Proc Natl Acad Sci . 2010;107:19961\u20136. Available from: https:\/\/pnas.org\/doi\/full\/10.1073\/pnas.1014465107.","DOI":"10.1073\/pnas.1014465107"},{"key":"2400_CR280","doi-asserted-by":"crossref","unstructured":"Zelante T, Iannitti RG, Cunha C, De Luca A, Giovannini G, Pieraccini G, et al. Tryptophan Catabolites from Microbiota Engage Aryl Hydrocarbon Receptor and Balance Mucosal Reactivity via Interleukin-22. Immunity . 2013;39:372\u201385. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1074761313003312.","DOI":"10.1016\/j.immuni.2013.08.003"},{"key":"2400_CR281","doi-asserted-by":"crossref","unstructured":"Bender MJ, McPherson AC, Phelps CM, Pandey SP, Laughlin CR, Shapira JH, et al. Dietary tryptophan metabolite released by intratumoral Lactobacillus reuteri facilitates immune checkpoint inhibitor treatment. Cell . 2023;186:1846\u20131862.e26. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0092867423002714.","DOI":"10.1016\/j.cell.2023.03.011"},{"key":"2400_CR282","doi-asserted-by":"crossref","unstructured":"Fong W, Li Q, Ji F, Liang W, Lau HCH, Kang X, et al. Lactobacillus gallinarum -derived metabolites boost anti-PD1 efficacy in colorectal cancer by inhibiting regulatory T cells through modulating IDO1\/Kyn\/AHR axis. Gut . 2023;72:2272\u201385. Available from: https:\/\/gut.bmj.com\/lookup\/doi\/10.1136\/gutjnl-2023-329543.","DOI":"10.1136\/gutjnl-2023-329543"},{"key":"2400_CR283","doi-asserted-by":"crossref","unstructured":"Jia D, Wang Q, Qi Y, Jiang Y, He J, Lin Y, et al. Microbial metabolite enhances immunotherapy efficacy by modulating T cell stemness in pan-cancer. Cell . 2024;187:1651\u20131665.e21. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0092867424002241.","DOI":"10.1016\/j.cell.2024.02.022"},{"key":"2400_CR284","doi-asserted-by":"crossref","unstructured":"Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti\u2013PD-L1 efficacy. Science (80- ) . 2015;350:1084\u20139. Available from: https:\/\/www.science.org\/doi\/10.1126\/science.aac4255.","DOI":"10.1126\/science.aac4255"},{"key":"2400_CR285","doi-asserted-by":"crossref","unstructured":"Chaput N, Lepage P, Coutzac C, Soularue E, Le Roux K, Monot C, et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol . 2017;28:1368\u201379. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419324317.","DOI":"10.1093\/annonc\/mdx108"},{"key":"2400_CR286","unstructured":"Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets T V., et al. Gut microbiome modulates response to anti\u2013PD-1 immunotherapy in melanoma patients. Science (80- ) . 2018;359:97\u2013103. Available from: https:\/\/www.science.org\/doi\/10.1126\/science.aan4236."},{"key":"2400_CR287","doi-asserted-by":"crossref","unstructured":"Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre M-L, et al. The commensal microbiome is associated with anti\u2013PD-1 efficacy in metastatic melanoma patients. Science (80- ) . 2018;359:104\u20138. Available from: https:\/\/www.science.org\/doi\/10.1126\/science.aao3290.","DOI":"10.1126\/science.aao3290"},{"key":"2400_CR288","doi-asserted-by":"crossref","unstructured":"Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daill\u00e8re R, et al. Gut microbiome influences efficacy of PD-1\u2013based immunotherapy against epithelial tumors. Science (80- ) . 2018;359:91\u20137. Available from: https:\/\/www.science.org\/doi\/10.1126\/science.aan3706.","DOI":"10.1126\/science.aan3706"},{"key":"2400_CR289","doi-asserted-by":"crossref","unstructured":"Jiang S-S, Xie Y-L, Xiao X-Y, Kang Z-R, Lin X-L, Zhang L, et al. Fusobacterium nucleatum-derived succinic acid induces tumor resistance to immunotherapy in colorectal cancer. Cell Host Microbe . 2023;31:781\u2013797.e9. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1931312823001610.","DOI":"10.1016\/j.chom.2023.04.010"},{"key":"2400_CR290","doi-asserted-by":"crossref","unstructured":"Routy B, Lenehan JG, Miller WH, Jamal R, Messaoudene M, Daisley BA, et al. Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial. Nat Med . 2023;29:2121\u201332. Available from: https:\/\/www.nature.com\/articles\/s41591-023-02453-x.","DOI":"10.1038\/s41591-023-02453-x"},{"key":"2400_CR291","doi-asserted-by":"crossref","unstructured":"Gopalakrishnan V, Helmink BA, Spencer CN, Reuben A, Wargo JA. The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy. Cancer Cell . 2018;33:570\u201380. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S153561081830120X.","DOI":"10.1016\/j.ccell.2018.03.015"},{"key":"2400_CR292","doi-asserted-by":"crossref","unstructured":"Baruch EN, Youngster I, Ben-Betzalel G, Ortenberg R, Lahat A, Katz L, et al. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science (80- ) . 2021;371:602\u20139. Available from: https:\/\/www.science.org\/doi\/10.1126\/science.abb5920.","DOI":"10.1126\/science.abb5920"},{"key":"2400_CR293","doi-asserted-by":"crossref","unstructured":"Davar D, Dzutsev AK, McCulloch JA, Rodrigues RR, Chauvin J-M, Morrison RM, et al. Fecal microbiota transplant overcomes resistance to anti\u2013PD-1 therapy in melanoma patients. Science (80- ). 2021;371:595\u2013602. Available from: https:\/\/www.science.org\/doi\/10.1126\/science.abf3363.","DOI":"10.1126\/science.abf3363"},{"key":"2400_CR294","doi-asserted-by":"crossref","unstructured":"Al-Hajj M, Clarke MF. Self-renewal and solid tumor stem cells. Oncogene . 2004;23:7274\u201382. Available from: https:\/\/www.nature.com\/articles\/1207947.","DOI":"10.1038\/sj.onc.1207947"},{"key":"2400_CR295","doi-asserted-by":"crossref","unstructured":"Schatton T, Sch\u00fctte U, Frank NY, Zhan Q, Hoerning A, Robles SC, et al. Modulation of T-Cell Activation by Malignant Melanoma Initiating Cells. Cancer Res . 2010;70:697\u2013708. Available from: https:\/\/aacrjournals.org\/cancerres\/article\/70\/2\/697\/559778\/Modulation-of-T-Cell-Activation-by-Malignant.","DOI":"10.1158\/0008-5472.CAN-09-1592"},{"key":"2400_CR296","doi-asserted-by":"crossref","unstructured":"Wang G, Xu J, Zhao J, Yin W, Liu D, Chen W, et al. Arf1-mediated lipid metabolism sustains cancer cells and its ablation induces anti-tumor immune responses in mice. Nat Commun . 2020;11:220. Available from: https:\/\/www.nature.com\/articles\/s41467-019-14046-9.","DOI":"10.1038\/s41467-019-14046-9"},{"key":"2400_CR297","doi-asserted-by":"crossref","unstructured":"Hou Y-C, Chao Y-J, Hsieh M-H, Tung H-L, Wang H-C, Shan Y-S. Low CD8+ T Cell Infiltration and High PD-L1 Expression Are Associated with Level of CD44+\/CD133+ Cancer Stem Cells and Predict an Unfavorable Prognosis in Pancreatic Cancer. Cancers (Basel) . 2019;11:541. Available from: https:\/\/www.mdpi.com\/2072-6694\/11\/4\/541.","DOI":"10.3390\/cancers11040541"},{"key":"2400_CR298","doi-asserted-by":"crossref","unstructured":"Hsu J-M, Xia W, Hsu Y-H, Chan L-C, Yu W-H, Cha J-H, et al. STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion. Nat Commun . 2018;9:1908. Available from: https:\/\/www.nature.com\/articles\/s41467-018-04313-6.","DOI":"10.1038\/s41467-018-04313-6"},{"key":"2400_CR299","doi-asserted-by":"crossref","unstructured":"Lee Y, Shin JH, Longmire M, Wang H, Kohrt HE, Chang HY, et al. CD44+ Cells in Head and Neck Squamous Cell Carcinoma Suppress T-Cell\u2013Mediated Immunity by Selective Constitutive and Inducible Expression of PD-L1. Clin Cancer Res . 2016;22:3571\u201381. Available from: https:\/\/aacrjournals.org\/clincancerres\/article\/22\/14\/3571\/79180\/CD44-Cells-in-Head-and-Neck-Squamous-Cell.","DOI":"10.1158\/1078-0432.CCR-15-2665"},{"key":"2400_CR300","doi-asserted-by":"crossref","unstructured":"Lou Y, Diao L, Cuentas ERP, Denning WL, Chen L, Fan YH, et al. Epithelial\u2013Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma. Clin Cancer Res . 2016;22:3630\u201342. Available from: https:\/\/aacrjournals.org\/clincancerres\/article\/22\/14\/3630\/79220\/Epithelial-Mesenchymal-Transition-Is-Associated.","DOI":"10.1158\/1078-0432.CCR-15-1434"},{"key":"2400_CR301","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1101\/gad.294348.116","volume":"31","author":"X Guo","year":"2017","unstructured":"Guo X, Zhao Y, Yan H, Yang Y, Shen S, Dai X, et al. Single tumor-initiating cells evade immune clearance by recruiting type II macrophages. Genes Dev. 2017;31:247\u201359.","journal-title":"Genes Dev"},{"key":"2400_CR302","doi-asserted-by":"crossref","unstructured":"Taniguchi S, Elhance A, Van Duzer A, Kumar S, Leitenberger JJ, Oshimori N. Tumor-initiating cells establish an IL-33\u2013TGF-\u03b2 niche signaling loop to promote cancer progression. Science (80- ) . 2020;369. Available from: https:\/\/www.science.org\/doi\/10.1126\/science.aay1813.","DOI":"10.1126\/science.aay1813"},{"key":"2400_CR303","doi-asserted-by":"crossref","unstructured":"Su W, Han HH, Wang Y, Zhang B, Zhou B, Cheng Y, et al. The Polycomb Repressor Complex 1 Drives Double-Negative Prostate Cancer Metastasis by Coordinating Stemness and Immune Suppression. Cancer Cell . 2019;36:139\u2013155.e10. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1535610819303009.","DOI":"10.1016\/j.ccell.2019.06.009"},{"key":"2400_CR304","doi-asserted-by":"crossref","unstructured":"Jia L, Zhang W, Wang C-Y. BMI1 Inhibition Eliminates Residual Cancer Stem Cells after PD1 Blockade and Activates Antitumor Immunity to Prevent Metastasis and Relapse. Cell Stem Cell . 2020;27:238\u2013253.e6. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1934590920302897.","DOI":"10.1016\/j.stem.2020.06.022"},{"key":"2400_CR305","doi-asserted-by":"crossref","unstructured":"Mortezaee K. Enriched cancer stem cells, dense stroma, and cold immunity: Interrelated events in pancreatic cancer. J Biochem Mol Toxicol . 2021;35. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jbt.22708.","DOI":"10.1002\/jbt.22708"},{"key":"2400_CR306","doi-asserted-by":"crossref","unstructured":"Najafi M, Mortezaee K, Majidpoor J. Stromal reprogramming: A target for tumor therapy. Life Sci . 2019;239:117049. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320519309762.","DOI":"10.1016\/j.lfs.2019.117049"},{"key":"2400_CR307","doi-asserted-by":"crossref","unstructured":"Lu I-N, Dobersalske C, Rauschenbach L, Teuber-Hanselmann S, Steinbach A, Ullrich V, et al. Tumor-associated hematopoietic stem and progenitor cells positively linked to glioblastoma progression. Nat Commun . 2021;12:3895. Available from: https:\/\/www.nature.com\/articles\/s41467-021-23995-z.","DOI":"10.1038\/s41467-021-23995-z"},{"key":"2400_CR308","doi-asserted-by":"crossref","unstructured":"Cheong J-H, Wang SC, Park S, Porembka MR, Christie AL, Kim H, et al. Development and validation of a prognostic and predictive 32-gene signature for gastric cancer. Nat Commun . 2022;13:774. Available from: https:\/\/www.nature.com\/articles\/s41467-022-28437-y.","DOI":"10.1038\/s41467-022-28437-y"},{"key":"2400_CR309","doi-asserted-by":"crossref","unstructured":"Wan S, Zhao E, Kryczek I, Vatan L, Sadovskaya A, Ludema G, et al. Tumor-Associated Macrophages Produce Interleukin 6 and Signal via STAT3 to Promote Expansion of Human Hepatocellular Carcinoma Stem Cells. Gastroenterology . 2014;147:1393\u2013404. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016508514010786.","DOI":"10.1053\/j.gastro.2014.08.039"},{"key":"2400_CR310","doi-asserted-by":"crossref","unstructured":"Wei J, Barr J, Kong L-Y, Wang Y, Wu A, Sharma AK, et al. Glioblastoma Cancer-Initiating Cells Inhibit T-Cell Proliferation and Effector Responses by the Signal Transducers and Activators of Transcription 3 Pathway. Mol Cancer Ther . 2010;9:67\u201378. Available from: https:\/\/aacrjournals.org\/mct\/article\/9\/1\/67\/93550\/Glioblastoma-Cancer-Initiating-Cells-Inhibit-T.","DOI":"10.1158\/1535-7163.MCT-09-0734"},{"key":"2400_CR311","doi-asserted-by":"crossref","unstructured":"Song TL, Nairism\u00e4gi M-L, Laurensia Y, Lim J-Q, Tan J, Li Z-M, et al. Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer\/T-cell lymphoma. Blood . 2018;132:1146\u201358. Available from: https:\/\/ashpublications.org\/blood\/article\/132\/11\/1146\/39381\/Oncogenic-activation-of-the-STAT3-pathway-drives.","DOI":"10.1182\/blood-2018-01-829424"},{"key":"2400_CR312","doi-asserted-by":"crossref","unstructured":"Kuo I-Y, Yang Y-E, Yang P-S, Tsai Y-J, Tzeng H-T, Cheng H-C, et al. Converged Rab37\/IL-6 trafficking and STAT3\/PD-1 transcription axes elicit an immunosuppressive lung tumor microenvironment. Theranostics . 2021;11:7029\u201344. Available from: https:\/\/www.thno.org\/v11p7029.htm.","DOI":"10.7150\/thno.60040"},{"key":"2400_CR313","doi-asserted-by":"crossref","unstructured":"Masibag AN, Bergin CJ, Haebe JR, Zouggar A, Shah MS, Sandouka T, et al. Pharmacological targeting of Sam68 functions in colorectal cancer stem cells. iScience . 2021;24:103442. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589004221014139.","DOI":"10.1016\/j.isci.2021.103442"},{"key":"2400_CR314","doi-asserted-by":"crossref","unstructured":"Chakrabarti R, Wei Y, Hwang J, Hang X, Andres Blanco M, Choudhury A, et al. \u0394Np63 promotes stem cell activity in mammary gland development and basal-like breast cancer by enhancing Fzd7 expression and Wnt signalling. Nat Cell Biol . 2014;16:1004\u201315. Available from: https:\/\/www.nature.com\/articles\/ncb3040.","DOI":"10.1038\/ncb3040"},{"key":"2400_CR315","doi-asserted-by":"crossref","unstructured":"Perry JM, Tao F, Roy A, Lin T, He XC, Chen S, et al. Overcoming Wnt\u2013\u03b2-catenin dependent anticancer therapy resistance in leukaemia stem cells. Nat Cell Biol . 2020;22:689\u2013700. Available from: https:\/\/www.nature.com\/articles\/s41556-020-0507-y.","DOI":"10.1038\/s41556-020-0507-y"},{"key":"2400_CR316","doi-asserted-by":"crossref","unstructured":"Takeuchi Y, Tanegashima T, Sato E, Irie T, Sai A, Itahashi K, et al. Highly immunogenic cancer cells require activation of the WNT pathway for immunological escape. Sci Immunol . 2021;6. Available from: https:\/\/www.science.org\/doi\/10.1126\/sciimmunol.abc6424.","DOI":"10.1126\/sciimmunol.abc6424"},{"key":"2400_CR317","doi-asserted-by":"crossref","unstructured":"Ganesh S, Shui X, Craig KP, Park J, Wang W, Brown BD, et al. RNAi-Mediated \u03b2-Catenin Inhibition Promotes T Cell Infiltration and Antitumor Activity in Combination with Immune Checkpoint Blockade. Mol Ther . 2018;26:2567\u201379. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001618304465.","DOI":"10.1016\/j.ymthe.2018.09.005"},{"key":"2400_CR318","doi-asserted-by":"crossref","unstructured":"He XC, Yin T, Grindley JC, Tian Q, Sato T, Tao WA, et al. PTEN-deficient intestinal stem cells initiate intestinal polyposis. Nat Genet . 2007;39:189\u201398. Available from: https:\/\/www.nature.com\/articles\/ng1928.","DOI":"10.1038\/ng1928"},{"key":"2400_CR319","doi-asserted-by":"crossref","unstructured":"Wei Y, Jiang Y, Zou F, Liu Y, Wang S, Xu N, et al. Activation of PI3K\/Akt pathway by CD133-p85 interaction promotes tumorigenic capacity of glioma stem cells. Proc Natl Acad Sci . 2013;110:6829\u201334. Available from: https:\/\/pnas.org\/doi\/full\/10.1073\/pnas.1217002110.","DOI":"10.1073\/pnas.1217002110"},{"key":"2400_CR320","doi-asserted-by":"crossref","unstructured":"Parsa AT, Waldron JS, Panner A, Crane CA, Parney IF, Barry JJ, et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med . 2007;13:84\u20138. Available from: https:\/\/www.nature.com\/articles\/nm1517.","DOI":"10.1038\/nm1517"},{"key":"2400_CR321","doi-asserted-by":"crossref","unstructured":"Verdys P, Johansen AZ, Gupta A, Presti M, Dionisio E, Madsen DH, et al. Acquired resistance to immunotherapy in solid tumors. Trends Mol Med . 2025; Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471491425000619.","DOI":"10.1016\/j.molmed.2025.03.010"},{"key":"2400_CR322","doi-asserted-by":"crossref","unstructured":"Saez-Iba\u00f1ez AR, Sommers E, Upadhaya S, Campbell J. PD1\/PDL1 clinical trials adapt to a growing landscape of patients resistant to PDx. Nat Rev Drug Discov . 2023;22:944\u20135. Available from: https:\/\/www.nature.com\/articles\/d41573-023-00179-6.","DOI":"10.1038\/d41573-023-00179-6"},{"issue":"3","key":"2400_CR323","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/d41573-020-00204-y","volume":"20","author":"S Upadhaya","year":"2021","unstructured":"Upadhaya S, Neftelino ST, Hodge JP, Oliva C, Campbell JR, Yu JX. Combinations take centre stage in PD1\/PDL1 inhibitor clinical trials. Nat Rev Drug Discov. 2021;20(3):168\u20139.","journal-title":"Nat. Rev. Drug Discov"},{"key":"2400_CR324","doi-asserted-by":"crossref","unstructured":"Yi M, Zheng X, Niu M, Zhu S, Ge H, Wu K. Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions. Mol Cancer . 2022;21:28. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/35062949.","DOI":"10.1186\/s12943-021-01489-2"},{"key":"2400_CR325","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob J-J, Rutkowski P, Lao CD, et al. Five-Year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381:1535\u201346. Available from: https:\/\/www.nejm.org\/doi\/full\/10.1056\/nejmoa1910836."},{"key":"2400_CR326","doi-asserted-by":"crossref","unstructured":"Jiang X, Rudqvist N-P, Jiang B, Ye S, He S, Liang Q, et al. Depletion of effector regulatory T cells associates with major response to induction dual immune checkpoint blockade. Cancer Discov . 2025; Available from: https:\/\/aacrjournals.org\/cancerdiscovery\/article\/doi\/10.1158\/2159-8290.CD-24-1390\/761919\/Depletion-of-effector-regulatory-T-cells.","DOI":"10.1158\/2159-8290.CD-24-1390"},{"key":"2400_CR327","doi-asserted-by":"crossref","unstructured":"Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim T-Y, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med . 2020;382:1894\u2013905. Available from: http:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa1915745.","DOI":"10.1056\/NEJMoa1915745"},{"key":"2400_CR328","doi-asserted-by":"crossref","unstructured":"Zhu AX, Abbas AR, de Galarreta MR, Guan Y, Lu S, Koeppen H, et al. Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. Nat Med . 2022;28:1599\u2013611. Available from: https:\/\/www.nature.com\/articles\/s41591-022-01868-2.","DOI":"10.1038\/s41591-022-01868-2"},{"key":"2400_CR329","doi-asserted-by":"crossref","unstructured":"Benmebarek M-R, Oguz C, Seifert M, Ruf B, Myojin Y, Bauer KC, et al. Anti-vascular endothelial growth factor treatment potentiates immune checkpoint blockade through a BAFF- and IL-12-dependent reprogramming of the TME. Immunity . 2025; Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1074761325000846.","DOI":"10.1016\/j.immuni.2025.02.017"},{"key":"2400_CR330","doi-asserted-by":"crossref","unstructured":"Andrews LP, Yano H, Vignali DAA. Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups. Nat Immunol. 2019;20:1425\u201334. Available from: https:\/\/europepmc.org\/article\/med\/31611702.","DOI":"10.1038\/s41590-019-0512-0"},{"key":"2400_CR331","doi-asserted-by":"crossref","unstructured":"Kiyozumi Y, Baba Y, Okadome K, Yagi T, Ishimoto T, Iwatsuki M, et al. IDO1 expression is associated with immune tolerance and poor prognosis in patients with surgically resected esophageal cancer. Ann Surg. 2019;269:1101\u20138. Available from: https:\/\/journals.lww.com\/annalsofsurgery\/fulltext\/2019\/06000\/ido1_expression_is_associated_with_immune.16.aspx.","DOI":"10.1097\/SLA.0000000000002754"},{"key":"2400_CR332","doi-asserted-by":"crossref","unstructured":"Cai L, Li Y, Tan J, Xu L, Li Y. Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy. J Hematol Oncol. 2023;16. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/37670328\/.","DOI":"10.1186\/s13045-023-01499-1"},{"key":"2400_CR333","doi-asserted-by":"crossref","unstructured":"Luke JJ, Gelmon K, Siu LL, Moreno V, Desai J, Gomez-Roca CA, et al. Phase 1\/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined with Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic Malignancies. Clin Cancer Res . 2025;31:2134\u201344. Available from: https:\/\/aacrjournals.org\/clincancerres\/article\/31\/11\/2134\/762531\/Phase-1-2-Study-of-the-Indoleamine-2-3-Dioxygenase.","DOI":"10.1158\/1078-0432.CCR-24-0439"},{"key":"2400_CR334","doi-asserted-by":"crossref","unstructured":"Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Guti\u00e9rrez E, et al. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. N Engl J Med . 2022;386:24\u201334. Available from: http:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa2109970.","DOI":"10.1056\/NEJMoa2109970"},{"key":"2400_CR335","doi-asserted-by":"crossref","unstructured":"de Gooyer PGM, Verschoor YL, van den Dungen LDW, Balduzzi S, Marsman HA, Geukes Foppen MH, et al. Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial. Nat Med 2024 . 2024;30:1\u20137. Available from: https:\/\/www.nature.com\/articles\/s41591-024-03250-w.","DOI":"10.1038\/s41591-024-03250-w"},{"key":"2400_CR336","doi-asserted-by":"crossref","unstructured":"Ascierto PA, Tang H, Dolfi S, Nyakas M, Marie Svane I, Mu\u00f1oz-Couselo E, et al. Effect of prior and first-line immunotherapy on baseline immune biomarkers and modulation of the tumor microenvironment in response to nivolumab and relatlimab combination therapy in patients with melanoma from RELATIVITY-020. J Immunother Cancer . 2025;13:e009773. Available from: https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2024-009773.","DOI":"10.1136\/jitc-2024-009773"},{"key":"2400_CR337","doi-asserted-by":"crossref","unstructured":"Li H, Zandberg DP, Kulkarni A, Chiosea SI, Santos PM, Isett BR, et al. Distinct CD8+ T cell dynamics associate with response to neoadjuvant cancer immunotherapies. Cancer Cell . 2025; Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1535610825000789.","DOI":"10.1016\/j.ccell.2025.02.026"},{"key":"2400_CR338","doi-asserted-by":"crossref","unstructured":"Banta KL, Xu X, Chitre AS, Au-Yeung A, Takahashi C, O\u2019Gorman WE, et al. Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8+ T cell responses. Immunity . 2022;55:512\u2013526.e9. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1074761322000851.","DOI":"10.1016\/j.immuni.2022.02.005"},{"key":"2400_CR339","doi-asserted-by":"crossref","unstructured":"Zhou X-M, Li W-Q, Wu Y-H, Han L, Cao X-G, Yang X-M, et al. Intrinsic Expression of Immune Checkpoint Molecule TIGIT Could Help Tumor Growth in vivo by Suppressing the Function of NK and CD8+ T Cells. Front Immunol . 2018;9. Available from: https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.02821\/full.","DOI":"10.3389\/fimmu.2018.02821"},{"key":"2400_CR340","unstructured":"Long G V., Shklovskaya E, Satgunaseelan L, Mao Y, da Silva IP, Perry KA, et al. Neoadjuvant triplet immune checkpoint blockade in newly diagnosed glioblastoma. Nat Med . 2025; Available from: https:\/\/www.nature.com\/articles\/s41591-025-03512-1."},{"key":"2400_CR341","doi-asserted-by":"crossref","unstructured":"Ascierto PA, Dummer R, Gaudy-Marqueste C, Bowyer S, Lipson EJ, Ghisoni E, et al. Efficacy and safety of triplet nivolumab, relatlimab, and ipilimumab (NIVO + RELA + IPI) in advanced melanoma: Results from RELATIVITY-048. J Clin Oncol . 2024;42:9504\u20139504. Available from: https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2024.42.16_suppl.9504.","DOI":"10.1200\/JCO.2024.42.16_suppl.9504"},{"key":"2400_CR342","doi-asserted-by":"crossref","unstructured":"Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, et al. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med . 2018;378:2288\u2013301. Available from: http:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa1716948.","DOI":"10.1056\/NEJMoa1716948"},{"key":"2400_CR343","doi-asserted-by":"crossref","unstructured":"Zhang Y, Chen H, Mo H, Zhao N, Sun X, Liu B, et al. Distinct cellular mechanisms underlie chemotherapies and PD-L1 blockade combinations in triple-negative breast cancer. Cancer Cell . 2025;43:446\u2013463.e7. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S153561082500025X.","DOI":"10.1016\/j.ccell.2025.01.007"},{"key":"2400_CR344","doi-asserted-by":"crossref","unstructured":"Rosenberg AJ, Perez CA, Guo W, de Oliveira Novaes JM, da Silva Reis KFO, McGarrah PW, et al. Breaking Ground in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Novel Therapies Beyond PD-L1 Immunotherapy. Am Soc Clin Oncol Educ B . 2024;44. Available from: https:\/\/ascopubs.org\/doi\/10.1200\/EDBK_433330.","DOI":"10.1200\/EDBK_433330"},{"key":"2400_CR345","doi-asserted-by":"crossref","unstructured":"Long Z, Grandis JR, Johnson DE. Emerging tyrosine kinase inhibitors for head and neck cancer. Expert Opin Emerg Drugs. 2022;27:333\u201344. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/36131561\/.","DOI":"10.1080\/14728214.2022.2125954"},{"key":"2400_CR346","unstructured":"Burtness B, Harrington KJ, Greil R, Souli\u00e8res D, Tahara M, de Castro G, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet . 2019;394:1915\u201328. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0140673619325917."},{"key":"2400_CR347","doi-asserted-by":"crossref","unstructured":"Taylor MH, Schmidt E V, Dutcus C, Pinheiro EM, Funahashi Y, Lubiniecki G, et al. The LEAP Program: Lenvatinib Plus Pembrolizumab for the Treatment of Advanced Solid Tumors. Futur Oncol . 2021;17:637\u201348. Available from: https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2020-0937.","DOI":"10.2217\/fon-2020-0937"},{"key":"2400_CR348","doi-asserted-by":"crossref","unstructured":"Hektoen HH, Tsuruda KM, Brustugun OT, Neumann K, Andreassen BK. Real-world comparison of pembrolizumab alone and combined with chemotherapy in metastatic lung adenocarcinoma patients with PD-L1 expression \u226550%. ESMO Open . 2025;10:105073. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702925009421.","DOI":"10.1016\/j.esmoop.2025.105073"},{"key":"2400_CR349","doi-asserted-by":"crossref","unstructured":"Zhu H, Shan Y, Ge K, Lu J, Kong W, Jia C. Oxaliplatin induces immunogenic cell death in hepatocellular carcinoma cells and synergizes with immune checkpoint blockade therapy. Cell Oncol . 2020;43:1203\u201314. Available from: https:\/\/link.springer.com\/10.1007\/s13402-020-00552-2.","DOI":"10.1007\/s13402-020-00552-2"},{"key":"2400_CR350","doi-asserted-by":"crossref","unstructured":"Zhang X-M, Yang T, Xu Y-Y, Li B-Z, Shen W, Hu W-Q, et al. Effectiveness and tolerability of programmed cell death protein-1 inhibitor + chemotherapy compared to chemotherapy for upper gastrointestinal tract cancers. World J Gastrointest Oncol . 2024;16:1613\u201325. Available from: https:\/\/www.wjgnet.com\/1948-5204\/full\/v16\/i4\/1613.htm.","DOI":"10.4251\/wjgo.v16.i4.1613"},{"key":"2400_CR351","doi-asserted-by":"crossref","unstructured":"Burris HA, Okusaka T, Vogel A, Lee MA, Takahashi H, Breder V, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2024;25:626\u201335. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/38697156\/.","DOI":"10.1016\/S1470-2045(24)00082-2"},{"key":"2400_CR352","doi-asserted-by":"crossref","unstructured":"Morris ZS, Demaria S, Monjazeb AM, Formenti SC, Weichselbaum RR, Welsh J, et al. Proceedings of the National Cancer Institute Workshop on combining immunotherapy with radiotherapy: challenges and opportunities for clinical translation. Lancet Oncol . 2025;26:e152\u201370. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1470204524006569.","DOI":"10.1016\/S1470-2045(24)00656-9"},{"key":"2400_CR353","doi-asserted-by":"crossref","unstructured":"Wu Y, Yan Y, Guo Y, Niu M, Zhou B, Zhang J, et al. Anti-TGF-\u03b2\/PD-L1 bispecific antibody synergizes with radiotherapy to enhance antitumor immunity and mitigate radiation-induced pulmonary fibrosis. J Hematol Oncol . 2025;18:24. Available from: https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-025-01678-2.","DOI":"10.1186\/s13045-025-01678-2"},{"key":"2400_CR354","doi-asserted-by":"crossref","unstructured":"Moore J, Gkantalis J, Guix I, Chou W, Yuen K, Lazar AA, et al. Identification of a conserved subset of cold tumors responsive to immune checkpoint blockade. J Immunother Cancer . 2025;13:e010528. Available from: https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2024-010528.","DOI":"10.1136\/jitc-2024-010528"},{"key":"2400_CR355","doi-asserted-by":"crossref","unstructured":"Ni H, Reitman ZJ, Zou W, Akhtar MN, Paul R, Huang M, et al. FLASH radiation reprograms lipid metabolism and macrophage immunity and sensitizes medulloblastoma to CAR-T cell therapy. Nat Cancer . 2025;6:460\u201373. Available from: https:\/\/www.nature.com\/articles\/s43018-025-00905-6.","DOI":"10.1038\/s43018-025-00905-6"},{"key":"2400_CR356","doi-asserted-by":"crossref","unstructured":"Ran X, Wu BX, Vidhyasagar V, Song L, Zhang X, Ladak RJ, et al. PARP inhibitor radiosensitization enhances anti-PD-L1 immunotherapy through stabilizing chemokine mRNA in small cell lung cancer. Nat Commun . 2025;16:2166. Available from: https:\/\/www.nature.com\/articles\/s41467-025-57257-z.","DOI":"10.1038\/s41467-025-57257-z"},{"key":"2400_CR357","doi-asserted-by":"crossref","unstructured":"Bando H, Kumagai S, Kotani D, Mishima S, Irie T, Itahashi K, et al. Atezolizumab following definitive chemoradiotherapy in patients with unresectable locally advanced esophageal squamous cell carcinoma \u2013 a multicenter phase 2 trial (EPOC1802). Nat Cancer . 2025; Available from: https:\/\/www.nature.com\/articles\/s43018-025-00918-1.","DOI":"10.1038\/s43018-025-00918-1"},{"key":"2400_CR358","doi-asserted-by":"crossref","unstructured":"Chen J, Levy A, Tian A-L, Huang X, Cai G, Fidelle M, et al. Low-dose irradiation of the gut improves the efficacy of PD-L1 blockade in metastatic cancer patients. Cancer Cell . 2025;43:361\u2013379.e10. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1535610825000625.","DOI":"10.1016\/j.ccell.2025.02.010"},{"key":"2400_CR359","doi-asserted-by":"crossref","unstructured":"Sakai SA, Saeki K, Chi S, Hamaya Y, Du J, Nakamura M, et al. Mathematical Modeling Predicts Optimal Immune Checkpoint Inhibitor and Radiotherapy Combinations and Timing of Administration. Cancer Immunol Res . 2025;13:353\u201364. Available from: https:\/\/aacrjournals.org\/cancerimmunolres\/article\/13\/3\/353\/752007\/Mathematical-Modeling-Predicts-Optimal-Immune.","DOI":"10.1158\/2326-6066.CIR-24-0610"},{"key":"2400_CR360","doi-asserted-by":"crossref","unstructured":"Smyth MJ, Ngiow SF, Ribas A, Teng MWL. Combination cancer immunotherapies tailored to the tumour microenvironment. Nat Rev Clin Oncol . 2016;13:143\u201358. Available from: https:\/\/www.nature.com\/articles\/nrclinonc.2015.209.","DOI":"10.1038\/nrclinonc.2015.209"},{"key":"2400_CR361","doi-asserted-by":"crossref","unstructured":"Zhu S, Zhang T, Zheng L, Liu H, Song W, Liu D, et al. Combination strategies to maximize the benefits of cancer immunotherapy. J Hematol Oncol . 2021;14:156. Available from: https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-021-01164-5.","DOI":"10.1186\/s13045-021-01164-5"},{"key":"2400_CR362","doi-asserted-by":"crossref","unstructured":"Page DB, Bear H, Prabhakaran S, Gatti-Mays ME, Thomas A, Cobain E, et al. Two may be better than one: PD-1\/PD-L1 blockade combination approaches in metastatic breast cancer. npj Breast Cancer . 2019;5:34. Available from: https:\/\/www.nature.com\/articles\/s41523-019-0130-x.","DOI":"10.1038\/s41523-019-0130-x"},{"key":"2400_CR363","doi-asserted-by":"crossref","unstructured":"Zhang J, Yan Y, Li J, Adhikari R, Fu L. PD-1\/PD-L1 Based Combinational Cancer Therapy: Icing on the Cake. Front Pharmacol . 2020;11. Available from: https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2020.00722\/full.","DOI":"10.3389\/fphar.2020.00722"},{"key":"2400_CR364","doi-asserted-by":"crossref","unstructured":"Xiong A, Wang L, Chen J, Wu L, Liu B, Yao J, et al. Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China. Lancet . 2025;405:839\u201349. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0140673624027223.","DOI":"10.1016\/S0140-6736(24)02722-3"},{"key":"2400_CR365","doi-asserted-by":"crossref","unstructured":"Cohen EE, Fayette J, Daste A, Even C, Tourneau C Le, Brana I, et al. Abstract CT012: Clinical activity of MCLA-158 (petosemtamab), an IgG1 bispecific antibody targeting EGFR and LGR5, in advanced head and neck squamous cell cancer (HNSCC). Cancer Res . 2023;83:CT012\u2013CT012. Available from: https:\/\/aacrjournals.org\/cancerres\/article\/83\/8_Supplement\/CT012\/725328\/Abstract-CT012-Clinical-activity-of-MCLA-158.","DOI":"10.1158\/1538-7445.AM2023-CT012"},{"key":"2400_CR366","doi-asserted-by":"crossref","unstructured":"Riechelmann H, Sauter A, Golze W, Hanft G, Schroen C, Hoermann K, et al. Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma. Oral Oncol . 2008;44:823\u20139. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1368837507002850.","DOI":"10.1016\/j.oraloncology.2007.10.009"},{"key":"2400_CR367","doi-asserted-by":"crossref","unstructured":"Li C, Yao J, Yang J, Zhang Y, Qiu Y, Zhu Z, et al. Preclinical evaluation of DB-1419, a novel bifunctional and bispecific anti-B7-H3\u00d7PD-L1 antibody-drug conjugate. Clin Cancer Res . 2025; Available from: https:\/\/aacrjournals.org\/clincancerres\/article\/doi\/10.1158\/1078-0432.CCR-25-0634\/762939\/Preclinical-evaluation-of-DB-1419-a-novel.","DOI":"10.1158\/1078-0432.CCR-25-0634"},{"key":"2400_CR368","doi-asserted-by":"crossref","unstructured":"Li X, Pan L, Li W, Liu B, Xiao C, Chew V, et al. Deciphering immune predictors of immunotherapy response: A multiomics approach at the pan-cancer level. Cell Reports Med . 2025;101992. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379125000655.","DOI":"10.1016\/j.xcrm.2025.101992"},{"key":"2400_CR369","doi-asserted-by":"crossref","unstructured":"Wang L-CS, Klooster R, Kulkarni A, de Vinuesa AG, Soloviev M, Hendriks LJ, et al. Abstract 2936: INCA33890, a novel PD-1\u00d7TGF\ua7b5R2 bispecific antibody conditionally antagonizes TGF\ua7b5 signaling in primary immune cells co-expressing PD-1. Cancer Res . 2023;83:2936\u20132936. Available from: https:\/\/aacrjournals.org\/cancerres\/article\/83\/7_Supplement\/2936\/724309\/Abstract-2936-INCA33890-a-novel-PD-1-TGF-R2.","DOI":"10.1158\/1538-7445.AM2023-2936"},{"key":"2400_CR370","doi-asserted-by":"crossref","unstructured":"Niu M, Yi M, Wu Y, Lyu L, He Q, Yang R, et al. Synergistic efficacy of simultaneous anti-TGF-\u03b2\/VEGF bispecific antibody and PD-1 blockade in cancer therapy. J Hematol Oncol . 2023;16:94. Available from: https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-023-01487-5.","DOI":"10.1186\/s13045-023-01487-5"},{"key":"2400_CR371","doi-asserted-by":"crossref","unstructured":"Zhao Y, Chen G, Chen J, Zhuang L, Du Y, Yu Q, et al. AK112, a novel PD-1\/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trial. eClinicalMedicine . 2023;62:102106. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537023002833.","DOI":"10.1016\/j.eclinm.2023.102106"},{"key":"2400_CR372","doi-asserted-by":"crossref","unstructured":"Yi M, Wu Y, Niu M, Zhu S, Zhang J, Yan Y, et al. Anti-TGF-\u03b2\/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer. J Immunother Cancer . 2022;10:e005543. Available from: https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2022-005543.","DOI":"10.1136\/jitc-2022-005543"},{"key":"2400_CR373","doi-asserted-by":"crossref","unstructured":"Newick K, O\u2019Brien S, Moon E, Albelda SM. CAR T Cell Therapy for Solid Tumors. Annu Rev Med . 2017;68:139\u201352. Available from: https:\/\/www.annualreviews.org\/doi\/10.1146\/annurev-med-062315-120245.","DOI":"10.1146\/annurev-med-062315-120245"},{"key":"2400_CR374","doi-asserted-by":"crossref","unstructured":"Uslu U, June CH. Beyond the blood: expanding CAR T cell therapy to solid tumors. Nat Biotechnol . 2025;43:506\u201315. Available from: https:\/\/www.nature.com\/articles\/s41587-024-02446-2.","DOI":"10.1038\/s41587-024-02446-2"},{"key":"2400_CR375","doi-asserted-by":"crossref","unstructured":"Yamaguchi Y, Gibson J, Ou K, Lopez LS, Ng RH, Leggett N, et al. PD-L1 blockade restores CAR T cell activity through IFN-\u03b3-regulation of CD163+ M2 macrophages. J Immunother Cancer . 2022;10:e004400. Available from: https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2021-004400.","DOI":"10.1136\/jitc-2021-004400"},{"key":"2400_CR376","doi-asserted-by":"crossref","unstructured":"Rossetti R, Brand H, Lima SCG, Furtado IP, Silveira RM, Fantacini DMC, et al. Combination of genetically engineered T cells and immune checkpoint blockade for the treatment of cancer. Immunother Adv . 2022;2. Available from: https:\/\/academic.oup.com\/immunotherapyadv\/article\/doi\/10.1093\/immadv\/ltac005\/6515365.","DOI":"10.1093\/immadv\/ltac005"},{"key":"2400_CR377","doi-asserted-by":"crossref","unstructured":"Du B, Qin J, Lin B, Zhang J, Li D, Liu M. CAR-T therapy in solid tumors. Cancer Cell . 2025;43:665\u201379. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1535610825001205.","DOI":"10.1016\/j.ccell.2025.03.019"},{"key":"2400_CR378","doi-asserted-by":"crossref","unstructured":"Qin L, Zhao R, Chen D, Wei X, Wu Q, Long Y, et al. Chimeric antigen receptor T cells targeting PD-L1 suppress tumor growth. Biomark Res . 2020;8:19. Available from: https:\/\/biomarkerres.biomedcentral.com\/articles\/10.1186\/s40364-020-00198-0.","DOI":"10.1186\/s40364-020-00198-0"},{"key":"2400_CR379","doi-asserted-by":"crossref","unstructured":"Luo Y, Gadd ME, Qie Y, Otamendi-Lopez A, Sanchez-Garavito JE, Brooks MM, et al. Solid cancer-directed CAR T cell therapy that attacks both tumor and immunosuppressive cells via targeting PD-L1. Mol Ther Oncol . 2024;32:200891. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950329924001334.","DOI":"10.1016\/j.omton.2024.200891"},{"key":"2400_CR380","doi-asserted-by":"crossref","unstructured":"AKME\u015eE \u00d6F. Data privacy-aware machine learning approach in pancreatic cancer diagnosis. BMC Med Inform Decis Mak. 2024;24:248. Available from: https:\/\/bmcmedinformdecismak.biomedcentral.com\/articles\/10.1186\/s12911-024-02657-2.","DOI":"10.1186\/s12911-024-02657-2"},{"key":"2400_CR381","unstructured":"Lee J. A machine learning toolkit for subtyping cancer in existing and new datasets. Nat Rev Cancer . 2025; Available from: https:\/\/www.nature.com\/articles\/s41568-025-00802-1."},{"key":"2400_CR382","doi-asserted-by":"crossref","unstructured":"Yates J, Van Allen EM. New horizons at the interface of artificial intelligence and translational cancer research. Cancer Cell . 2025;43:708\u201327. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1535610825001199.","DOI":"10.1016\/j.ccell.2025.03.018"},{"key":"2400_CR383","doi-asserted-by":"crossref","unstructured":"Kong J, Ha D, Lee J, Kim I, Park M, Im S-H, et al. Network-based machine learning approach to predict immunotherapy response in cancer patients. Nat Commun . 2022;13:3703. Available from: https:\/\/www.nature.com\/articles\/s41467-022-31535-6.","DOI":"10.1038\/s41467-022-31535-6"},{"key":"2400_CR384","doi-asserted-by":"crossref","unstructured":"Li Y, Wu X, Fang D, Luo Y. Informing immunotherapy with multi-omics driven machine learning. npj Digit Med . 2024;7:67. Available from: https:\/\/www.nature.com\/articles\/s41746-024-01043-6.","DOI":"10.1038\/s41746-024-01043-6"},{"key":"2400_CR385","doi-asserted-by":"crossref","unstructured":"Wang Q, Zhou Y, Yang H, Zhang J, Zeng X, Tan Y. MRI\u2010based clinical\u2010radiomics nomogram model for predicting microvascular invasion in hepatocellular carcinoma. Med Phys . 2024;51:4673\u201386. Available from: https:\/\/aapm.onlinelibrary.wiley.com\/doi\/10.1002\/mp.17087.","DOI":"10.1002\/mp.17087"},{"key":"2400_CR386","doi-asserted-by":"crossref","unstructured":"Poirion OB, Jing Z, Chaudhary K, Huang S, Garmire LX. DeepProg: an ensemble of deep-learning and machine-learning models for prognosis prediction using multi-omics data. Genome Med . 2021;13:112. Available from: https:\/\/genomemedicine.biomedcentral.com\/articles\/10.1186\/s13073-021-00930-x.","DOI":"10.1186\/s13073-021-00930-x"},{"key":"2400_CR387","doi-asserted-by":"crossref","unstructured":"Zheng X, Mund A, Mann M. Deciphering functional tumor-immune crosstalk through highly multiplexed imaging and deep visual proteomics. Mol Cell . 2025;85:1008\u20131023.e7. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1097276524010414.","DOI":"10.1016\/j.molcel.2024.12.023"},{"key":"2400_CR388","doi-asserted-by":"crossref","unstructured":"Fomin V, So WV, Barbieri RA, Hiller-Bittrolff K, Koletou E, Tu T, et al. Machine learning identifies clinical tumor mutation landscape pathways of resistance to checkpoint inhibitor therapy in NSCLC. J Immunother Cancer . 2025;13:e009092. Available from: https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2024-009092.","DOI":"10.1136\/jitc-2024-009092"},{"key":"2400_CR389","doi-asserted-by":"crossref","unstructured":"Liu Z, Yang Z, Wu J, Zhang W, Sun Y, Zhang C, et al. A single-cell atlas reveals immune heterogeneity in anti-PD-1-treated non-small cell lung cancer. Cell . 2025;188:3081\u20133096.e19. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0092867425002910.","DOI":"10.1016\/j.cell.2025.03.018"},{"key":"2400_CR390","unstructured":"Chang T-G, Cao Y, Sfreddo HJ, Dhruba SR, Lee S-H, Valero C, et al. LORIS robustly predicts patient outcomes with immune checkpoint blockade therapy using common clinical, pathologic and genomic features. Nat Cancer . 2024; Available from: https:\/\/www.nature.com\/articles\/s43018-024-00772-7."},{"key":"2400_CR391","unstructured":"Yoo S-K, Fitzgerald CW, Cho BA, Fitzgerald BG, Han C, Koh ES, et al. Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data. Nat Med . 2025; Available from: https:\/\/www.nature.com\/articles\/s41591-024-03398-5."},{"key":"2400_CR392","doi-asserted-by":"crossref","unstructured":"Luo C, Zhang R, Guo R, Wu L, Xue T, He Y, et al. Integrated computational analysis identifies therapeutic targets with dual action in cancer cells and T cells. Immunity . 2025;58:745\u2013765.e9. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S107476132500072X.","DOI":"10.1016\/j.immuni.2025.02.007"},{"key":"2400_CR393","doi-asserted-by":"crossref","unstructured":"Sahni S, Wang B, Wu D, Dhruba SR, Nagy M, Patkar S, et al. A machine learning model reveals expansive downregulation of ligand-receptor interactions that enhance lymphocyte infiltration in melanoma with developed resistance to immune checkpoint blockade. Nat Commun . 2024;15:8867. Available from: https:\/\/www.nature.com\/articles\/s41467-024-52555-4.","DOI":"10.1038\/s41467-024-52555-4"},{"key":"2400_CR394","doi-asserted-by":"crossref","unstructured":"Chen Q, Zhao B, Tan Z, Kogner P, Ljungblad L. Resource Systems-level immunomonitoring in children with solid tumors to enable precision medicine Systems-level immunomonitoring in children with solid tumors to enable precision medicine. Cell. 2025;188(5):1425\u20131440-e11.","DOI":"10.1016\/j.cell.2024.12.014"},{"key":"2400_CR395","doi-asserted-by":"crossref","unstructured":"Gao Q, Yang L, Lu M, Jin R, Ye H, Ma T. The artificial intelligence and machine learning in lung cancer immunotherapy. J Hematol Oncol . 2023;16:55. Available from:https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-023-01456-y.","DOI":"10.1186\/s13045-023-01456-y"},{"key":"2400_CR396","doi-asserted-by":"crossref","unstructured":"Bao R, Hutson A, Madabhushi A, Jonsson VD, Rosario SR, Barnholtz-Sloan JS, et al. Ten challenges and opportunities in computational immuno-oncology. J Immunother Cancer . 2024;12:e009721. Available from: https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2024-009721.","DOI":"10.1136\/jitc-2024-009721"},{"key":"2400_CR397","unstructured":"de Gooyer PGM, Verschoor YL, van den Dungen LDW, Balduzzi S, Marsman HA, Geukes Foppen MH, et al. Artificial intelligence-based biomarkers for treatment decisions in oncology. Trends in Cancer . 2025;11:232\u201344. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405803324002802."},{"key":"2400_CR398","doi-asserted-by":"crossref","unstructured":"Chu G, Shan W, Ji X, Wang Y, Niu H. Multi-Omics Analysis of Novel Signature for Immunotherapy Response and Tumor Microenvironment Regulation Patterns in Urothelial Cancer. Front Cell Dev Biol . 2021;9. Available from: https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2021.764125\/full.","DOI":"10.3389\/fcell.2021.764125"},{"key":"2400_CR399","doi-asserted-by":"crossref","unstructured":"Parra ER, Zhang J, Duose DY, Gonzalez-Kozlova E, Redman MW, Chen H, et al. Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial. Clin Cancer Res. 2024;30:1655\u201368. Available from: https:\/\/aacrjournals.org\/clincancerres\/article\/30\/8\/1655\/742118\/Multi-omics-Analysis-Reveals-Immune-Features.","DOI":"10.1158\/1078-0432.CCR-23-0251"},{"key":"2400_CR400","doi-asserted-by":"crossref","unstructured":"Sayaman RW, Saad M, Thorsson V, Hu D, Hendrickx W, Roelands J, et al. Germline genetic contribution to the immune landscape of cancer. Immunity . 2021;54:367\u2013386.e8. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1074761321000340.","DOI":"10.1016\/j.immuni.2021.01.011"},{"key":"2400_CR401","unstructured":"Tirosh I, Izar B, Prakadan SM, Wadsworth MH, Treacy D, Trombetta JJ, et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science (80- ) . 2016;352:189\u201396. Available from: https:\/\/www.science.org\/doi\/10.1126\/science.aad0501."},{"key":"2400_CR402","doi-asserted-by":"crossref","unstructured":"Cui X, Liu S, Song H, Xu J, Sun Y. Single-cell and spatial transcriptomic analyses revealing tumor microenvironment remodeling after neoadjuvant chemoimmunotherapy in non-small cell lung cancer. Mol Cancer . 2025;24:111. Available from: https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-025-02287-w.","DOI":"10.1186\/s12943-025-02287-w"},{"key":"2400_CR403","doi-asserted-by":"crossref","unstructured":"Lehti\u00f6 J, Arslan T, Siavelis I, Pan Y, Socciarelli F, Berkovska O, et al. Proteogenomics of non-small cell lung cancer reveals molecular subtypes associated with specific therapeutic targets and immune-evasion mechanisms. Nat Cancer . 2021;2:1224\u201342. Available from: https:\/\/www.nature.com\/articles\/s43018-021-00259-9.","DOI":"10.1038\/s43018-021-00259-9"},{"key":"2400_CR404","doi-asserted-by":"crossref","unstructured":"Zhang P, Pei S, Zhou G, Zhang M, Zhang L, Zhang Z. Purine metabolism in lung adenocarcinoma: A single\u2010cell analysis revealing prognostic and immunotherapeutic insights. J Cell Mol Med . 2024;28. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jcmm.18284.","DOI":"10.1111\/jcmm.18284"},{"key":"2400_CR405","doi-asserted-by":"crossref","unstructured":"Ruan X, Lai C, Li L, Wang B, Lu X, Zhang D, et al. Integrative analysis of single-cell and bulk multi-omics data to reveal subtype-specific characteristics and therapeutic strategies in clear cell renal cell carcinoma patients. J Cancer . 2024;15:6420\u201333. Available from: https:\/\/www.jcancer.org\/v15p6420.htm.","DOI":"10.7150\/jca.101451"},{"key":"2400_CR406","doi-asserted-by":"crossref","unstructured":"Jiang A, Liu Y, Chen O, Liu Z, Cai H, Wang L, et al. Editorial: Multi-omics approaches for decoding heterogeneity in cancer immunotherapy. Front Pharmacol . 2023;14. Available from: https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1324212\/full.","DOI":"10.3389\/fphar.2023.1324212"},{"key":"2400_CR407","doi-asserted-by":"crossref","unstructured":"Quek C, Pratapa A, Bai X, Al-Eryani G, Pires da Silva I, Mayer A, et al. Single-cell spatial multiomics reveals tumor microenvironment vulnerabilities in cancer resistance to immunotherapy. Cell Rep . 2024;43:114392. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211124724007204.","DOI":"10.1016\/j.celrep.2024.114392"},{"key":"2400_CR408","doi-asserted-by":"crossref","unstructured":"Liu X-H, Wang G-R, Zhong N-N, Wang W-Y, Liu B, Li Z, et al. Multi-omics in immunotherapy research for HNSCC: present situation and future perspectives. npj Precis Oncol . 2025;9:93. Available from: https:\/\/www.nature.com\/articles\/s41698-025-00886-w.","DOI":"10.1038\/s41698-025-00886-w"},{"key":"2400_CR409","doi-asserted-by":"crossref","unstructured":"Jing Y, Liu J, Ye Y, Pan L, Deng H, Wang Y, et al. Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy. Nat Commun. 2020;11:1\u20137. Available from: https:\/\/www.nature.com\/articles\/s41467-020-18742-9.","DOI":"10.1038\/s41467-020-18742-9"},{"key":"2400_CR410","doi-asserted-by":"crossref","unstructured":"Zhang Q, Wang Z, Zeng X, Ding Y, Wang C. Evaluation of tumorous LCP1 and ADPGK as predictive biomarker for immune-related adverse events in bone and soft tissue sarcomas treated with anti-PD-1 and anti-PD-L1 antibodies. BMC Cancer. 2025;25:619. Available from: https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-14007-0.","DOI":"10.1186\/s12885-025-14007-0"},{"key":"2400_CR411","doi-asserted-by":"crossref","unstructured":"Desharnais L, Sorin M, Rezanejad M, Liu B, Karimi E, Atallah A, et al. Spatially mapping the tumour immune microenvironments of non-small cell lung cancer. Nat Commun . 2025;16:1345. Available from: https:\/\/www.nature.com\/articles\/s41467-025-56546-x.","DOI":"10.1038\/s41467-025-56546-x"},{"key":"2400_CR412","doi-asserted-by":"crossref","unstructured":"Walsh LA, Quail DF. Decoding the tumor microenvironment with spatial technologies. Nat Immunol . 2023;24:1982\u201393. Available from: https:\/\/www.nature.com\/articles\/s41590-023-01678-9.","DOI":"10.1038\/s41590-023-01678-9"},{"key":"2400_CR413","doi-asserted-by":"crossref","unstructured":"Zeng D, Fang Y, Qiu W, Luo P, Wang S, Shen R, et al. Enhancing immuno-oncology investigations through multidimensional decoding of tumor microenvironment with IOBR 2.0. Cell Reports Methods . 2024;4:100910. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266723752400300X.","DOI":"10.1016\/j.crmeth.2024.100910"},{"key":"2400_CR414","doi-asserted-by":"crossref","unstructured":"Chen H, Deng C, Gao J, Wang J, Fu F, Wang Y, et al. Integrative spatial analysis reveals tumor heterogeneity and immune colony niche related to clinical outcomes in small cell lung cancer. Cancer Cell . 2025;43:519\u2013536.e5. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1535610825000303.","DOI":"10.1016\/j.ccell.2025.01.012"},{"key":"2400_CR415","doi-asserted-by":"crossref","unstructured":"Shiao SL, Gouin KH, Ing N, Ho A, Basho R, Shah A, et al. Single-cell and spatial profiling identify three response trajectories to pembrolizumab and radiation therapy in triple negative breast cancer. Cancer Cell . 2024;42:70\u201384.e8. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1535610823004403.","DOI":"10.1016\/j.ccell.2023.12.012"},{"key":"2400_CR416","doi-asserted-by":"crossref","unstructured":"Cheng X, Tang C, Dong K, You Y, Zhao X, Duan B, et al. SpaLinker identifies phenotype-associated spatial tumor microenvironment features by integrating bulk and spatial sequencing data. Cell Genomics . 2025;100893. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666979X25001491.","DOI":"10.1016\/j.xgen.2025.100893"},{"key":"2400_CR417","doi-asserted-by":"crossref","unstructured":"Reina-Campos M, Farhi SL, Benoist C. ImmGenMaps, an open-source cartography of the immune system. Nat Immunol . 2025; Available from: https:\/\/www.nature.com\/articles\/s41590-025-02119-5.","DOI":"10.1038\/s41590-025-02119-5"},{"key":"2400_CR418","unstructured":"Nadig A, Replogle JM, Pogson AN, Murthy M, McCarroll SA, Weissman JS, et al. Transcriptome-wide analysis of differential expression in perturbation atlases. Nat Genet . 2025; Available from: https:\/\/www.nature.com\/articles\/s41588-025-02169-3."},{"key":"2400_CR419","doi-asserted-by":"crossref","unstructured":"Zhu X, Hu M, Huang X, Li L, Lin X, Shao X, et al. Interplay between gut microbial communities and metabolites modulates pan-cancer immunotherapy responses. Cell Metab . 2025;37:806\u2013823.e6. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1550413124004959.","DOI":"10.1016\/j.cmet.2024.12.013"},{"key":"2400_CR420","doi-asserted-by":"crossref","unstructured":"Brandenburg A, Heine A, Brossart P. Next-generation cancer vaccines and emerging immunotherapy combinations. Trends in Cancer . 2024;10:749\u201369. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405803324001171.","DOI":"10.1016\/j.trecan.2024.06.003"},{"key":"2400_CR421","doi-asserted-by":"crossref","unstructured":"Aunins EA, Phan AT, Alameh M-G, Dwivedi G, Cruz-Morales E, Christian DA, et al. An Il12 mRNA-LNP adjuvant enhances mRNA vaccine\u2013induced CD8 T cell responses. Sci Immunol . 2025;10. Available from: https:\/\/www.science.org\/doi\/10.1126\/sciimmunol.ads1328.","DOI":"10.1126\/sciimmunol.ads1328"},{"key":"2400_CR422","doi-asserted-by":"crossref","unstructured":"Peters D, Kranz LM, Eisel D, Diken M, Kreiter S, T\u00fcreci \u00d6, et al. RNA-encoded Interleukin 2 with Extended Bioavailability Amplifies RNA Vaccine\u2013Induced Antitumor T-cell Immunity. Cancer Immunol Res . 2024;12:1409\u201320. Available from: https:\/\/aacrjournals.org\/cancerimmunolres\/article\/12\/10\/1409\/748723\/RNA-encoded-Interleukin-2-with-Extended.","DOI":"10.1158\/2326-6066.CIR-23-0701"},{"key":"2400_CR423","doi-asserted-by":"crossref","unstructured":"Gao Y, Nihira NT, Bu X, Chu C, Zhang J, Kolodziejczyk A, et al. Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy. Nat Cell Biol. 2020;22:1064\u201375. Available from: https:\/\/www.nature.com\/articles\/s41556-020-0562-4.","DOI":"10.1038\/s41556-020-0562-4"},{"key":"2400_CR424","doi-asserted-by":"crossref","unstructured":"Liu Y, Yang Z, Wang S, Miao R, Chang C-WM, Zhang J, et al. Nuclear PD-L1 compartmentalization suppresses tumorigenesis and overcomes immunocheckpoint therapy resistance in mice via histone macroH2A1. J Clin Invest . 2024;134. Available from: https:\/\/www.jci.org\/articles\/view\/181314.","DOI":"10.1172\/JCI181314"},{"key":"2400_CR425","doi-asserted-by":"crossref","unstructured":"Wang JS, Yassin S, Lin AY. Utilization of exosome-based therapies to augment anti-PD-1\/PD-L1 therapies. J Immunother Cancer . 2025;13:e010603. Available from: https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2024-010603.","DOI":"10.1136\/jitc-2024-010603"},{"key":"2400_CR426","doi-asserted-by":"crossref","unstructured":"Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet . 2014;384:1109\u201317. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0140673614609582.","DOI":"10.1016\/S0140-6736(14)60958-2"},{"key":"2400_CR427","doi-asserted-by":"crossref","unstructured":"Patnaik A, Kang SP, Rasco D, Papadopoulos KP, Elassaiss-Schaap J, Beeram M, et al. Phase I Study of Pembrolizumab (MK-3475; Anti\u2013PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors. Clin Cancer Res . 2015;21:4286\u201393. Available from: https:\/\/aacrjournals.org\/clincancerres\/article\/21\/19\/4286\/125563\/Phase-I-Study-of-Pembrolizumab-MK-3475-Anti-PD-1.","DOI":"10.1158\/1078-0432.CCR-14-2607"},{"key":"2400_CR428","doi-asserted-by":"crossref","unstructured":"Gadgeel S, Rodr\u00edguez-Abreu D, Speranza G, Esteban E, Felip E, D\u00f3mine M, et al. Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non\u2013Small-Cell Lung Cancer. J Clin Oncol . 2020;38:1505\u201317. Available from: https:\/\/ascopubs.org\/doi\/10.1200\/JCO.19.03136.","DOI":"10.1200\/JCO.19.03136"},{"key":"2400_CR429","doi-asserted-by":"crossref","unstructured":"Gandhi L, Rodr\u00edguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus Chemotherapy in Metastatic Non\u2013Small-Cell Lung Cancer. N Engl J Med . 2018;378:2078\u201392. Available from: http:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa1801005.","DOI":"10.1056\/NEJMoa1801005"},{"key":"2400_CR430","doi-asserted-by":"crossref","unstructured":"de Castro G, Kudaba I, Wu Y-L, Lopes G, Kowalski DM, Turna HZ, et al. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non\u2013Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score \u2265 1% in the KEYNOTE-042 Study. J Clin Oncol . 2023;41:1986\u201391. Available from: https:\/\/ascopubs.org\/doi\/10.1200\/JCO.21.02885.","DOI":"10.1200\/JCO.21.02885"},{"key":"2400_CR431","doi-asserted-by":"crossref","unstructured":"Bang Y-J, Kang Y-K, Catenacci D V., Muro K, Fuchs CS, Geva R, et al. Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study. Gastric Cancer . 2019;22:828\u201337. Available from: http:\/\/link.springer.com\/10.1007\/s10120-018-00909-5.","DOI":"10.1007\/s10120-018-00909-5"},{"key":"2400_CR432","doi-asserted-by":"crossref","unstructured":"Verset G, Borbath I, Karwal M, Verslype C, Van Vlierberghe H, Kardosh A, et al. Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial. Clin Cancer Res . 2022;28:2547\u201354. Available from: https:\/\/aacrjournals.org\/clincancerres\/article\/28\/12\/2547\/699289\/Pembrolizumab-Monotherapy-for-Previously-Untreated.","DOI":"10.1158\/1078-0432.CCR-21-3807"},{"key":"2400_CR433","doi-asserted-by":"crossref","unstructured":"Chatterjee M, Turner DC, Felip E, Lena H, Cappuzzo F, Horn L, et al. Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer. Ann Oncol . 2016;27:1291\u20138. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419356984.","DOI":"10.1093\/annonc\/mdw174"},{"key":"2400_CR434","doi-asserted-by":"crossref","unstructured":"Hamid O, Puzanov I, Dummer R, Schachter J, Daud A, Schadendorf D, et al. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. Eur J Cancer . 2017;86:37\u201345. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804917311425.","DOI":"10.1016\/j.ejca.2017.07.022"},{"key":"2400_CR435","doi-asserted-by":"crossref","unstructured":"Robert C, Schachter J, Long G V, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med . 2015;372:2521\u201332. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25891173.","DOI":"10.1056\/NEJMoa1503093"},{"key":"2400_CR436","unstructured":"Motzer R, Alekseev B, Rha S-Y, Porta C, Eto M, Powles T, et al. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. N Engl J Med . 2021;384:1289\u2013300. Available from: http:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa2035716."},{"key":"2400_CR437","doi-asserted-by":"crossref","unstructured":"Monk BJ, Colombo N, Tewari KS, Dubot C, Caceres MV, Hasegawa K, et al. First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826. J Clin Oncol . 2023;41:5505\u201311. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/37910822.","DOI":"10.1200\/JCO.23.00914"},{"key":"2400_CR438","unstructured":"Mok TSK, Wu Y-L, Kudaba I, Kowalski DM, Cho BC, Turna HZ, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet . 2019;393:1819\u201330. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0140673618324097."},{"key":"2400_CR439","doi-asserted-by":"crossref","unstructured":"Herbst RS, Baas P, Kim D-W, Felip E, P\u00e9rez-Gracia JL, Han J-Y, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet . 2016;387:1540\u201350. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0140673615012817.","DOI":"10.1016\/S0140-6736(15)01281-7"},{"key":"2400_CR440","doi-asserted-by":"crossref","unstructured":"Langer CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, Patnaik A, Powell SF, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol . 2016;17:1497\u2013508. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1470204516304983.","DOI":"10.1016\/S1470-2045(16)30498-3"},{"key":"2400_CR441","doi-asserted-by":"crossref","unstructured":"Larkin J, Minor D, D\u2019Angelo S, Neyns B, Smylie M, Miller WH, et al. Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator\u2019s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial. J Clin Oncol. 2018;36:383\u201390. Available from: https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2016.71.8023.","DOI":"10.1200\/JCO.2016.71.8023"},{"key":"2400_CR442","doi-asserted-by":"crossref","unstructured":"Ferris RL, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med . 2016;375:1856\u201367. Available from: http:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa1602252.","DOI":"10.1056\/NEJMoa1602252"},{"key":"2400_CR443","doi-asserted-by":"crossref","unstructured":"Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol . 2017;18:312\u201322. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1470204517300657.","DOI":"10.1016\/S1470-2045(17)30065-7"},{"key":"2400_CR444","doi-asserted-by":"crossref","unstructured":"Schmid S, Diem S, Li Q, Krapf M, Flatz L, Leschka S, et al. Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC). Cancer Immunol Immunother. 2018;67:1825\u201332. Available from: http:\/\/link.springer.com\/10.1007\/s00262-018-2239-4.","DOI":"10.1007\/s00262-018-2239-4"},{"key":"2400_CR445","doi-asserted-by":"crossref","unstructured":"Larkin J, Weber J, Del Vecchio M, Gogas H, Arance AM, Dalle S, et al. Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria. Eur J Cancer . 2022;173:285\u201396. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804922003926.","DOI":"10.1016\/j.ejca.2022.06.041"},{"key":"2400_CR446","doi-asserted-by":"crossref","unstructured":"Brahmer J, Reckamp KL, Baas P, Crin\u00f2 L, Eberhardt WEE, Poddubskaya E, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non\u2013Small-Cell Lung Cancer. N Engl J Med . 2015;373:123\u201335. Available from: http:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa1504627.","DOI":"10.1056\/NEJMoa1504627"},{"key":"2400_CR447","unstructured":"Rizvi NA, Mazi\u00e8res J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol . 2015;16:257\u201365. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1470204515700549."},{"key":"2400_CR448","doi-asserted-by":"crossref","unstructured":"Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non\u2013Small-Cell Lung Cancer. N Engl J Med . 2015;373:1627\u201339. Available from: http:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa1507643.","DOI":"10.1056\/NEJMoa1507643"},{"key":"2400_CR449","doi-asserted-by":"crossref","unstructured":"Antonia SJ, L\u00f3pez-Martin JA, Bendell J, Ott PA, Taylor M, Eder JP, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1\/2 trial. Lancet Oncol . 2016;17:883\u201395. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1470204516300985.","DOI":"10.1016\/S1470-2045(16)30098-5"},{"key":"2400_CR450","doi-asserted-by":"crossref","unstructured":"Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med . 2015;373:1803\u201313. Available from: http:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa1510665.","DOI":"10.1056\/NEJMoa1510665"},{"key":"2400_CR451","doi-asserted-by":"crossref","unstructured":"Motzer RJ, Tannir NM, McDermott DF, Ar\u00e9n Frontera O, Melichar B, Choueiri TK, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018;378:1277\u201390. Available from: http:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa1712126.","DOI":"10.1056\/NEJMoa1712126"},{"key":"2400_CR452","doi-asserted-by":"publisher","first-page":"4240","DOI":"10.1200\/JCO.20.02295","volume":"38","author":"RR McKay","year":"2020","unstructured":"McKay RR, McGregor BA, Xie W, Braun DA, Wei X, Kyriakopoulos CE, et al. Optimized management of Nivolumab and Ipilimumab in advanced renal cell carcinoma: a response-based phase II study (OMNIVORE). J Clin Oncol. 2020;38:4240\u20138. https:\/\/doi.org\/10.1200\/JCO.20.02295.","journal-title":"J Clin Oncol"},{"key":"2400_CR453","doi-asserted-by":"crossref","unstructured":"Ai L, Chen J, Yan H, He Q, Luo P, Xu Z, et al. Research status and outlook of pd-1\/pd-l1 inhibitors for cancer therapy. Drug Des Devel Ther. Dove Press; 2020:3625\u201349. Available from: https:\/\/www.pmc\/articles\/PMC7490077\/.","DOI":"10.2147\/DDDT.S267433"},{"key":"2400_CR454","doi-asserted-by":"crossref","unstructured":"Stratigos AJ, Sekulic A, Peris K, Bechter O, Prey S, Kaatz M, et al. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. Lancet Oncol. 2021;22:848\u201357. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1470204521001261.","DOI":"10.1016\/S1470-2045(21)00126-1"},{"key":"2400_CR455","doi-asserted-by":"crossref","unstructured":"Gogishvili M, Melkadze T, Makharadze T, Giorgadze D, Dvorkin M, Penkov K, et al. Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial. Nat Med . 2022;28:2374\u201380. Available from: https:\/\/www.nature.com\/articles\/s41591-022-01977-y.","DOI":"10.1038\/s41591-022-01977-y"},{"key":"2400_CR456","unstructured":"Mai H-Q, Chen Q-Y, Chen D, Hu C, Yang K, Wen J, et al. Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial. Nat Med . 2021;27:1536\u201343. Available from: https:\/\/www.nature.com\/articles\/s41591-021-01444-0."},{"key":"2400_CR457","doi-asserted-by":"crossref","unstructured":"Wang F, Wei XL, Wang FH, Xu N, Shen L, Dai GH, et al. Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib\/II clinical trial NCT02915432. Ann Oncol . 2019;30:1479\u201386. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419459887.","DOI":"10.1093\/annonc\/mdz197"},{"key":"2400_CR458","doi-asserted-by":"crossref","unstructured":"Wang F-H, Wei X-L, Feng J, Li Q, Xu N, Hu X-C, et al. Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02). J Clin Oncol . 2021;39:704\u201312. Available from: https:\/\/ascopubs.org\/doi\/10.1200\/JCO.20.02712.","DOI":"10.1200\/JCO.20.02712"},{"key":"2400_CR459","doi-asserted-by":"crossref","unstructured":"Yang J, Dong L, Yang S, Han X, Han Y, Jiang S, et al. Safety and clinical efficacy of toripalimab, a PD-1 mAb, in patients with advanced or recurrent malignancies in a phase I study. Eur J Cancer . 2020;130:182\u201392. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095980492030068X.","DOI":"10.1016\/j.ejca.2020.01.028"},{"key":"2400_CR460","doi-asserted-by":"crossref","unstructured":"Gutzmer R, Stroyakovskiy D, Gogas H, Robert C, Lewis K, Protsenko S, et al. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. Lancet . 2020;395:1835\u201344. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014067362030934X.","DOI":"10.1016\/S0140-6736(20)30934-X"},{"key":"2400_CR461","doi-asserted-by":"crossref","unstructured":"Ning Y-M, Suzman D, Maher VE, Zhang L, Tang S, Ricks T, et al. FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum-Containing Chemotherapy. Oncologist . 2017;22:743\u20139. Available from: https:\/\/academic.oup.com\/oncolo\/article\/22\/6\/743\/6439392.","DOI":"10.1634\/theoncologist.2017-0087"},{"key":"2400_CR462","doi-asserted-by":"crossref","unstructured":"Balar A V, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet (London, England) . 2017;389:67\u201376. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27939400.","DOI":"10.1016\/S0140-6736(16)32455-2"},{"key":"2400_CR463","doi-asserted-by":"crossref","unstructured":"Hoffman-Censits JH, Grivas P, Heijden MS Van Der, Dreicer R, Loriot Y, Retz M, et al. IMvigor 210, a phase II trial of atezolizumab (MPDL3280A) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC). 2016;34:355. Available from: https:\/\/www.ascopubs.org\/doi\/10.1200\/jco.2016.34.2_suppl.355.","DOI":"10.1200\/jco.2016.34.2_suppl.355"},{"key":"2400_CR464","doi-asserted-by":"crossref","unstructured":"Powles T, Dur\u00e1n I, van der Heijden MS, Loriot Y, Vogelzang NJ, De Giorgi U, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet . 2018;391:748\u201357. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014067361733297X.","DOI":"10.1016\/S0140-6736(17)33297-X"},{"key":"2400_CR465","doi-asserted-by":"crossref","unstructured":"Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet . 2017;389:255\u201365. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014067361632517X.","DOI":"10.1016\/S0140-6736(16)32517-X"},{"key":"2400_CR466","doi-asserted-by":"crossref","unstructured":"Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet . 2016;387:1837\u201346. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0140673616005870.","DOI":"10.1016\/S0140-6736(16)00587-0"},{"key":"2400_CR467","doi-asserted-by":"crossref","unstructured":"Felip E, Altorki N, Zhou C, Cs\u0151szi T, Vynnychenko I, Goloborodko O, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB\u2013IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet . 2021;398:1344\u201357. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0140673621020985.","DOI":"10.1016\/S0140-6736(21)02098-5"},{"key":"2400_CR468","doi-asserted-by":"crossref","unstructured":"Herbst RS, Giaccone G, de Marinis F, Reinmuth N, Vergnenegre A, Barrios CH, et al. Atezolizumab for First-Line Treatment of PD-L1\u2013Selected Patients with NSCLC. N Engl J Med . 2020;383:1328\u201339. Available from: http:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa1917346.","DOI":"10.1056\/NEJMoa1917346"},{"key":"2400_CR469","doi-asserted-by":"crossref","unstructured":"Horn L, Mansfield AS, Szcz\u0119sna A, Havel L, Krzakowski M, Hochmair MJ, et al. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N Engl J Med. 2018;379:2220\u20139. Available from: http:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa1809064.","DOI":"10.1056\/NEJMoa1809064"},{"key":"2400_CR470","unstructured":"Powles T, van der Heijden MS, Castellano D, Galsky MD, Loriot Y, Petrylak DP, et al. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol . 2020;21:1574\u201388. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1470204520305416."},{"key":"2400_CR471","doi-asserted-by":"crossref","unstructured":"Levy A, Massard C, Soria J-C, Deutsch E. Concurrent irradiation with the anti-programmed cell death ligand-1 immune checkpoint blocker durvalumab: Single centre subset analysis from a phase 1\/2 trial. Eur J Cancer . 2016;68:156\u201362. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804916324340.","DOI":"10.1016\/j.ejca.2016.09.013"},{"key":"2400_CR472","unstructured":"Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after Chemoradiotherapy in Stage III Non\u2013Small-Cell Lung Cancer. N Engl J Med . 2017;377:1919\u201329. Available from: http:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa1709937."},{"key":"2400_CR473","doi-asserted-by":"crossref","unstructured":"Hui R, \u00d6zg\u00fcro\u011flu M, Villegas A, Daniel D, Vicente D, Murakami S, et al. Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study. Lancet Oncol . 2019;20:1670\u201380. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1470204519305194.","DOI":"10.1016\/S1470-2045(19)30519-4"},{"key":"2400_CR474","doi-asserted-by":"crossref","unstructured":"Antonia S, Goldberg SB, Balmanoukian A, Chaft JE, Sanborn RE, Gupta A, et al. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. Lancet Oncol . 2016;17:299\u2013308. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1470204515005446.","DOI":"10.1016\/S1470-2045(15)00544-6"},{"key":"2400_CR475","doi-asserted-by":"crossref","unstructured":"Creelan BC, Yeh TC, Kim S-W, Nogami N, Kim D-W, Chow LQM, et al. A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced\/metastatic non-small-cell lung cancer. Br J Cancer . 2021;124:383\u201390. Available from: https:\/\/www.nature.com\/articles\/s41416-020-01099-7.","DOI":"10.1038\/s41416-020-01099-7"},{"key":"2400_CR476","doi-asserted-by":"crossref","unstructured":"Bharmal M, Guillemin I, Marrel A, Arnould B, Lambert J, Hennessy M, et al. How to address the challenges of evaluating treatment benefits-risks in rare diseases? A convergent mixed methods approach applied within a Merkel cell carcinoma phase 2 clinical trial. Orphanet J Rare Dis . 2018;13:95. Available from: https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-018-0835-1.","DOI":"10.1186\/s13023-018-0835-1"},{"key":"2400_CR477","doi-asserted-by":"crossref","unstructured":"Novakovic AM, Wilkins JJ, Dai H, Wade JR, Neuteboom B, Brar S, et al. Changing Body Weight\u2013Based Dosing to a Flat Dose for Avelumab in Metastatic Merkel Cell and Advanced Urothelial Carcinoma. Clin Pharmacol Ther . 2020;107:588\u201396. Available from: https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.1645.","DOI":"10.1002\/cpt.1645"},{"key":"2400_CR478","doi-asserted-by":"crossref","unstructured":"Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, et al. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med . 2019;380:1103\u201315. Available from: http:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa1816047.","DOI":"10.1056\/NEJMoa1816047"},{"key":"2400_CR479","doi-asserted-by":"crossref","unstructured":"Choueiri TK, Motzer RJ, Rini BI, Haanen J, Campbell MT, Venugopal B, et al. Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. Ann Oncol . 2020;31:1030\u20139. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092375342039308X.","DOI":"10.1016\/j.annonc.2020.04.010"},{"key":"2400_CR480","doi-asserted-by":"crossref","unstructured":"Pophali P, Varela JC, Rosenblatt J. Immune checkpoint blockade in hematological malignancies: current state and future potential. Front Oncol . 2024;14. Available from: https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1323914\/full.","DOI":"10.3389\/fonc.2024.1323914"},{"key":"2400_CR481","doi-asserted-by":"crossref","unstructured":"Lu Y, Yuan X, Wang M, He Z, Li H, Wang J, et al. Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies. J Hematol Oncol . 2022;15:47. Available from: https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-022-01273-9.","DOI":"10.1186\/s13045-022-01273-9"},{"key":"2400_CR482","doi-asserted-by":"crossref","unstructured":"Dhodapkar M V., Dhodapkar KM. Immune Modulation in Hematologic Malignancies. Semin Oncol . 2015;42:617\u201325. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775415001074.","DOI":"10.1053\/j.seminoncol.2015.05.009"},{"key":"2400_CR483","doi-asserted-by":"crossref","unstructured":"Chen BJ, Chapuy B, Ouyang J, Sun HH, Roemer MGM, Xu ML, et al. PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies. Clin Cancer Res . 2013;19:3462\u201373. Available from: https:\/\/aacrjournals.org\/clincancerres\/article\/19\/13\/3462\/208517\/PD-L1-Expression-Is-Characteristic-of-a-Subset-of.","DOI":"10.1158\/1078-0432.CCR-13-0855"},{"key":"2400_CR484","doi-asserted-by":"crossref","unstructured":"Mercier FE, Ragu C, Scadden DT. The bone marrow at the crossroads of blood and immunity. Nat Rev Immunol . 2012;12:49\u201360. Available from: https:\/\/www.nature.com\/articles\/nri3132.","DOI":"10.1038\/nri3132"},{"key":"2400_CR485","doi-asserted-by":"crossref","unstructured":"Thompson ED, Enriquez HL, Fu Y-X, Engelhard VH. Tumor masses support naive T cell infiltration, activation, and differentiation into effectors. J Exp Med . 2010;207:1791\u2013804. Available from: https:\/\/rupress.org\/jem\/article\/207\/8\/1791\/46061\/Tumor-masses-support-naive-T-cell-infiltration.","DOI":"10.1084\/jem.20092454"},{"key":"2400_CR486","doi-asserted-by":"crossref","unstructured":"Gao D. The role of non-malignant B cells in malignant hematologic diseases. Hematology . 2025;30. Available from: https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/16078454.2025.2466261.","DOI":"10.1080\/16078454.2025.2466261"},{"key":"2400_CR487","doi-asserted-by":"crossref","unstructured":"Xie Y, Yang H, Yang C, He L, Zhang X, Peng L, et al. Role and Mechanisms of Tumor-Associated Macrophages in Hematological Malignancies. Front Oncol . 2022;12. Available from: https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.933666\/full.","DOI":"10.3389\/fonc.2022.933666"},{"key":"2400_CR488","doi-asserted-by":"crossref","unstructured":"Melssen MM, Sheybani ND, Leick KM, Slingluff CL. Barriers to immune cell infiltration in tumors. J Immunother Cancer . 2023;11:e006401. Available from: https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2022-006401.","DOI":"10.1136\/jitc-2022-006401"},{"key":"2400_CR489","doi-asserted-by":"crossref","unstructured":"Yang L, Rau R, Goodell MA. DNMT3A in haematological malignancies. Nat Rev Cancer . 2015;15:152\u201365. Available from: https:\/\/www.nature.com\/articles\/nrc3895.","DOI":"10.1038\/nrc3895"},{"key":"2400_CR490","doi-asserted-by":"crossref","unstructured":"Rodr\u00edguez-Ubreva J, Catal\u00e0-Moll F, Obermajer N, \u00c1lvarez-Errico D, Ramirez RN, Company C, et al. Prostaglandin E2 Leads to the Acquisition of DNMT3A-Dependent Tolerogenic Functions in Human Myeloid-Derived Suppressor Cells. Cell Rep . 2017;21:154\u201367. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211124717312792.","DOI":"10.1016\/j.celrep.2017.09.018"},{"key":"2400_CR491","doi-asserted-by":"crossref","unstructured":"Feng Y, Li X, Cassady K, Zou Z, Zhang X. TET2 Function in Hematopoietic Malignancies, Immune Regulation, and DNA Repair. Front Oncol . 2019;9. Available from:https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2019.00210\/full.","DOI":"10.3389\/fonc.2019.00210"},{"key":"2400_CR492","doi-asserted-by":"crossref","unstructured":"Delhommeau F, Dupont S, Valle V Della, James C, Trannoy S, Mass\u00e9 A, et al. Mutation in TET2 in Myeloid Cancers. N Engl J Med . 2009;360:2289\u2013301. Available from: http:\/\/www.nejm.org\/doi\/abs\/10.1056\/NEJMoa0810069.","DOI":"10.1056\/NEJMoa0810069"},{"key":"2400_CR493","doi-asserted-by":"crossref","unstructured":"Huang Y, Qin Y, He Y, Qiu D, Zheng Y, Wei J, et al. Advances in molecular targeted drugs in combination with CAR-T cell therapy for hematologic malignancies. Drug Resist Updat. 2024;74:101082. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1368764624000402.","DOI":"10.1016\/j.drup.2024.101082"},{"key":"2400_CR494","doi-asserted-by":"crossref","unstructured":"Ghosh A, Barba P, Perales M. Checkpoint inhibitors in AML: are we there yet? Br J Haematol . 2020;188:159\u201367. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.16358.","DOI":"10.1111\/bjh.16358"},{"key":"2400_CR495","doi-asserted-by":"crossref","unstructured":"Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin\u2019s Lymphoma. N Engl J Med . 2015;372:311\u20139. Available from: http:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa1411087.","DOI":"10.1056\/NEJMoa1411087"},{"key":"2400_CR496","doi-asserted-by":"crossref","unstructured":"Gogas H, Dr\u00e9no B, Larkin J, Demidov L, Stroyakovskiy D, Eroglu Z, et al. Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase III IMspire170 study. Ann Oncol . 2021;32:384\u201394. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092375342043203X.","DOI":"10.1016\/j.annonc.2020.12.004"},{"key":"2400_CR497","doi-asserted-by":"crossref","unstructured":"Juliano C. Coelho. Atezolizumab Monotherapy as First-line Treatment in Patients with Advanced BRAFV600 Wild-type Melanoma. J Clin Haematol. 2021;2. Available from: https:\/\/www.scientificarchives.com\/article\/atezolizumab-monotherapy-as-first-line-treatment-in-patients-with-advanced-brafv600-wild-type-melanoma.","DOI":"10.33696\/haematology.2.034"},{"key":"2400_CR498","doi-asserted-by":"crossref","unstructured":"Lan Y, Zhang D, Xu C, Hance KW, Marelli B, Qi J, et al. Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-\u03b2. Sci Transl Med . 2018;10. Available from: https:\/\/www.science.org\/doi\/10.1126\/scitranslmed.aan5488.","DOI":"10.1126\/scitranslmed.aan5488"},{"key":"2400_CR499","doi-asserted-by":"crossref","unstructured":"Liu D, Gong J, Liu T, Li K, Yin X, Liu Y, et al. Phase 1 study of SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-\u03b2, in patients with advanced solid tumors. J Clin Oncol . 2021;39:2503\u20132503. Available from: https:\/\/www.ascopubs.org\/doi\/10.1200\/JCO.2021.39.15_suppl.2503.","DOI":"10.1200\/JCO.2021.39.15_suppl.2503"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02400-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-025-02400-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02400-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T01:05:07Z","timestamp":1759885507000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-025-02400-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,8]]},"references-count":499,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2400"],"URL":"https:\/\/doi.org\/10.1186\/s12943-025-02400-z","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,8]]},"assertion":[{"value":"18 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"246"}}